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Abstract
Background: Approximately one million stillbirths occur annually during labour; most of these stillbirths
occur in low and middle-income countries and are associated with absent, inadequate, or delayed obstetric
care. The low proportion of intrapartum stillbirths in high-income countries suggests that intrapartum
stillbirths are largely preventable with quality intrapartum care, including prompt recognition and
management of intrapartum complications. The evidence for impact of intrapartum interventions on
stillbirth and perinatal mortality outcomes has not yet been systematically examined.
Methods: We undertook a systematic review of the published literature, searching PubMed and the
Cochrane Library, of trials and reviews (N = 230) that reported stillbirth or perinatal mortality outcomes
for eight interventions delivered during labour. Where eligible randomised controlled trials had been
published after the most recent Cochrane review on any given intervention, we incorporated these new
trial findings into a new meta-analysis with the Cochrane included studies.
Results: We found a paucity of studies reporting statistically significant evidence of impact on perinatal
mortality, especially on stillbirths. Available evidence suggests that operative delivery, especially Caesarean
section, contributes to decreased stillbirth rates. Induction of labour rather than expectant management in
post-term pregnancies showed strong evidence of impact, though there was not enough evidence to
suggest superior safety for the fetus of any given drug or drugs for induction of labour. Planned Caesarean
section for term breech presentation has been shown in a large randomised trial to reduce stillbirths, but
the feasibility and consequences of implementing this intervention routinely in low-/middle-income
countries add caveats to recommending its use. Magnesium sulphate for pre-eclampsia and eclampsia is
effective in preventing eclamptic seizures, but studies have not demonstrated impact on perinatal mortality.
There was limited evidence of impact for maternal hyperoxygenation, and concerns remain about maternal
safety. Transcervical amnioinfusion for meconium staining appears promising for low/middle income-
country application according to the findings of many small studies, but a large randomised trial of the
intervention had no significant impact on perinatal mortality, suggesting that further studies are needed.
Conclusion:  Although the global appeal to prioritise access to emergency obstetric care, especially
vacuum extraction and Caesarean section, rests largely on observational and population-based data, these
interventions are clearly life-saving in many cases of fetal compromise. Safe, comprehensive essential and
emergency obstetric care is particularly needed, and can make the greatest impact on stillbirth rates, in low-
resource settings. Other advanced interventions such as amnioinfusion and hyperoxygenation may reduce
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perinatal mortality, but concerns about safety and effectiveness require further study before they can be
routinely included in programs.
Introduction
Stillbirths, or late fetal deaths, account for more than half
of the world's 6 million perinatal deaths that occur in low-
/middle-income countries each year. While stillbirth rates
are commonly as low as 3 to 5 per 1000 births in some
high-income countries, their incidence is estimated to be
five to ten times greater in many low-/middle-income
countries. These higher stillbirth rates are believed to be
attributable to poor baseline maternal health (especially
nutritional status), poor prevention and treatment of
maternal conditions and infections during pregnancy,
and inappropriate management of complications during
pregnancy and childbirth.
There are two kinds of intrauterine fetal deaths: those that
occur prior to the onset of labour (antepartum stillbirths),
and those that occur during labour (intrapartum still-
births). The major causes of antepartum stillbirths are
pregnancy complications that lead to fetal asphyxia and/
or infection, including maternal infections, hypertensive
disorders, placental dysfunction and haemorrhage, and
fetal or placental abnormalities. The specific causes of
many antepartum stillbirths, however, are difficult to
ascertain. In low-/middle-income countries, approxi-
mately one-third of stillbirths are estimated to occur intra-
partum, and these are caused primarily by complications
arising during labour and childbirth, such as prolonged or
obstructed labour or umbilical cord accidents [1,2].
Intervention strategies to prevent antepartum and intra-
partum stillbirths differ because they have largely different
causes. Where women receive quality intrapartum care, as
in many high-income countries, the proportion of intra-
partum stillbirths is less than 10% of all stillbirths [2],
indicating that a substantial proportion of intrapartum
stillbirths are preventable with quality intrapartum care.
Yet half of the world's women give birth at home, in the
absence of a skilled birth attendant. Globally, the intra-
partum stillbirth rate is estimated to be between 7 and 9
per 1000 births [2-4], but this figure obscures wide dispar-
ities both within and among countries, including substan-
tial urban-rural and rich-poor divides. The risk of an
intrapartum stillbirth in low and middle-income coun-
tries is more than 14 times that in high-income countries;
the risk is 17 times higher in low-income than in middle-
income countries. When women in low-/middle-income
countries do give birth in health facilities, their care and
their pregnancy outcomes are frequently compromised by
absent or overburdened health care providers; deficiencies
in training and supervision; insufficient supplies, drugs,
and equipment; and substandard hygienic practices.
This paper focuses on interventions delivered during
childbirth, primarily care provided at secondary- and ter-
tiary-level large teaching and research hospitals with sur-
gical capacity, that are of potential benefit for perinatal
health and prevention of stillbirths.
Methods
Detailed methods undertaken to assemble and assess the
evidence for the interventions in this paper are given in
the first paper in this series [5]. Each study was given a
level of evidence (LOE) according to the SIGN grading sys-
tem. Grade of evidence, (i.e. A, B, C, D) was determined
and then the interventions were classified under clear evi-
dence, some evidence, uncertain evidence or evidence of
no or negative impact, as detailed in paper 1 [5]. We
included 8 obstetric care interventions in our analysis
(Table 1).
Results
Instrumental delivery (vacuum and forceps-assisted)
Background
Instrumental vaginal deliveries, which make up a subset
of operative deliveries, are procedures involving traction
applied to the fetal head, for indications including mater-
nal exhaustion or other compromise (e.g., maternal heart
disease), fetal distress or heart rate abnormalities (often
associated with prolonged second stage of labour), and
fetal malposition [6]. Rates of instrumental deliveries
Table 1: Interventions to prevent intrapartum stillbirth reviewed in this paper
• Instrumental delivery (vacuum and forceps-assisted)
• Emergency obstetric care, including Caesarean section
• Induction of labour versus expectant management
• Drugs for cervical ripening and induction of labour
• Planned Caesarean section for breech presentation
• Magnesium sulphate for treatment of pre-eclampsia/eclampsia or pre-term labour
• Maternal hyperoxygenation for suspected impaired fetal growth
• AmnioinfusionBMC Pregnancy and Childbirth 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2393/9/S1/S6
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range from 5–20% in high-income countries [6]. Before
an instrumental delivery should be attempted, the fetal
head must be engaged and its position known, the cervix
fully dilated, and the membranes ruptured. Traction is
generally applied to the fetal head with either forceps or a
vacuum extraction device (also called a ventouse). The use
of these devices poses the potential for injury to the
mother or the baby. Forceps have long been associated
with birth trauma, particularly when used for rotational
procedures, but low overall morbidity rates are reported
for well-trained forceps practitioners [7]. While the associ-
ation with birth injury is fairly well established, whether
forceps use or vacuum extraction is preferable for prevent-
ing stillbirth or perinatal mortality is unclear.
Literature-based evidence
Our systematic review included 2 Cochrane reviews and 5
other observational and intervention studies (Table 2).
No studies were found that compared stillbirth outcomes
with versus without instrumental vaginal delivery. One
Cochrane review by Johanson et al. [7] compared the
impact of vacuum extraction to forceps delivery, and
included 7 trials reporting perinatal mortality outcomes
(Additional file 1). Vacuum extraction compared to for-
ceps delivery was associated with significantly less mater-
nal trauma (OR = 0.41, 95% CI: 0.33–0.50) and less
general and regional anaesthesia. Additionally, the risk of
Caesarean section showed a trend towards being lower
among the vacuum extractor group than the forceps group
(OR = 0.56, 95% CI: 0.31–1.02 [NS]). Vacuum extraction
was more likely to fail when used for assisted vaginal
delivery than forceps (OR = 1.69, 95% CI: 1.31–2.19).
Perinatal mortality rates were not statistically significantly
different between the two instrumental methods (7 trials,
N = 1800, OR = 0.80, 95% CI: 0.18–3.52 vacuum extrac-
tion vs. forceps, respectively). The vacuum extractor was
associated with an increase in neonatal cephalhaemoto-
mas and retinal haemorrhages, but serious neonatal
injury was uncommon with either instrument and Apgar
scores at 1 and 5 min were comparable [LOE: 1+]. The
other Cochrane review, also by Johanson et al. [8], com-
pared the impact of use of soft versus rigid vacuum extrac-
tor cups; only one trial (N = 72) in Malaysia reported
perinatal death as an outcome but found no significant
difference between soft and hard cups (OR = 1.26, 95%
CI: 0.08–20.85 [NS]) [LOE: 1+] (Additional file 2).
An RCT by Weerasekera et al. [9] not included in the
above reviews compared the outcomes associated with
vacuum and forceps deliveries (N = 442 women) in the
second stage of labour. There were no significant differ-
ences between the two methods in the incidence of third-
degree perineal tears, postpartum haemorrhage or rup-
tured uterus, but cervical tears were slightly higher in the
forceps group. Cephalhaematoma incidence was higher
among the vacuum extraction group, but there were no
significant differences between the groups in babies need-
ing resuscitation at birth, admission to neonatal intensive
care unit, stillbirth or neonatal death rates [LOE: 2+].
Another RCT from Pakistan reported similar success rates
with both instruments [10].
Multiple observational studies have evaluated the compli-
cations and outcomes related to vacuum deliveries either
alone or in comparison with alternative methods of
instrumental deliveries [11,12]. In a prospective study of
167 vacuum extractions (6.3% of total deliveries) at the
national hospital in Kenya, Gachiri et al. [13] docu-
mented perinatal morbidity and mortality rates of 16.2%
and 4.8% respectively [LOE: 3]. Lurie et al [14] conducted
a decision-to-delivery time analysis and found that it was
faster to undertake forceps deliveries compared to vacuum
extractions. While some studies suggested higher rates of
vaginal tears with forceps [15], in general no differences in
complication rates were found in other studies [16], and
no studies found differences in stillbirth incidence.
New meta-analysis
We identified 7 trials comparing vacuum extraction versus
forceps-assisted deliveries that reported stillbirth inci-
dence (N = 632 vacuum, N = 611 forceps). Our meta-anal-
ysis found no evidence of differential impact of either
method on stillbirths (OR = 0.60, 95% CI: 0.07–5.00)
(Figure 1).
Conclusion
Although vacuum extraction was associated with a trend
toward lower Caesarean section rates and fewer significant
maternal injuries and less anaesthetic requirement than
forceps delivery, there was no difference in rates of intra-
partum stillbirth or perinatal mortality. Vacuum extrac-
tion tended to be associated with increased, albeit low,
risk of neonatal cephalohaematoma and retinal haemor-
rhage. The lower rate of Caesarean section despite higher
failure rate among vacuum extractions may be due to
superiority of the vacuum for managing certain fetal mal-
positions (such as deflexed occipital posterior position,
for example), or more likely, because following a failed
vacuum extraction, delivery is usually by forceps, while
failed forceps is usually followed by Caesarean section
[7,17]. The reduced maternal morbidity and limited,
largely short-term risk of neonatal complications associ-
ated with vacuum extraction suggest that although there is
no evidence that either method is superior to the other in
preventing stillbirths, vacuum extraction may be prefera-
ble in areas where vacuum extractors are available and
practitioners are suitably trained to perform vacuum
extraction [17]. In other areas where forceps deliveries are
the norm and health practitioners do not have training in
vacuum extraction, the significant investment needed forBMC Pregnancy and Childbirth 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2393/9/S1/S6
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the purchase of vacuum extractors and quality training to
capacitate practitioners to perform the procedure may be
prohibitive for certain low-resource settings. Relatively
inexpensive manual vacuum extractors are available that
may require less training to use than forceps and may be
a useful alternative to forceps to facilitate rapid delivery in
the presence of signs of fetal distress in the second stage of
labour; however, these require further evaluation.
Table 2: Comparison of impact of vacuum extractor versus forceps on stillbirths and perinatal mortality
Source Location and Type of Study Intervention Stillbirths/Perinatal Outcomes
Reviews and meta-analyses
Johanson and Menon 1999 [7] USA, Denmark, Sweden, England, 
South Africa.
Meta-analysis (Cochrane). 7 RCTs 
included (N = 1800 women).
Assessed the effects of vacuum 
extraction vs. forceps on maternal 
and neonatal morbidity.
PMR: OR = 0.80 (95% CI: 0.18–
3.52) [NS].
[3/901 vs. 4/899 in vacuum vs. 
forceps group, respectively].
Johanson and Menon 2000 [8] Malaysia.
Cochrane review. 1 RCT included 
with death as outcome (N = 72 
women).
To assess the effects of soft 
(intervention) vs. rigid vacuum 
extractor cups (control) on perineal 
injury, fetal scalp injury and success 
rate.
Death: OR = 1.26 (95% CI: 0.08–
20.85) [NS].
[1/32 vs. 1/40 in intervention and 
control groups, respectively].
Intervention studies
Mustafa and Mustafa 2002 [10] Pakistan (Multan). Nishtar Hospital.
RCT. Consecutive patients (N = 
931), of which 50 were selected (N 
= 27 ventouse group, N = 23 
forceps).
50/931 consecutive patients were 
randomly selected either to forceps 
delivery (Group I) or ventouse 
extraction (Group II).
Compared the effects of ventouse 
vs. forceps delivery on maternal and 
perinatal outcome.
SBR: 0/27 vs. 1/23 in the vacuum 
and forceps groups, respectively.
Success rate: 26/27 (96.30%) vs. 22/
23 (95.65%) in vacuum and forceps 
groups, respectively.
There was one failure in each 
category which was later on 
delivered by Caesarean section.
Weerasekera et al. 2002 [9] Sri Lanka. Tertiary care setting.
RCT. Women (N = 442) 
undergoing instrumental delivery in 
the second stage (N = 238 forceps 
group, N = 204 vacuum).
Compared the impact of forceps vs. 
vacuum delivery on the stillbirth 
rate.
SBR or NMR: 1/238 vs. 1/204 in the 
forceps and vacuum groups, 
respectively; P > 0.05.
There was no significant difference 
in babies needing resuscitation at 
birth or admission to neonatal 
intensive care unit.
Observational studies
Broekhuizen et al. 1987 [11] USA. Tertiary care setting.
Retrospective study. N = 256 
vacuum extractions, and N = 300 
randomly chosen forceps deliveries 
were analyzed.
Compared the impact of the vacuum 
extraction vs. forceps deliveries.
Death: one event in each group.
Gachiri et al. 1991 [13] Kenya (Nairobi). Kenyatta National 
Hospital.
Prospective study. Vacuum 
extractions (N = 167).
Assessed the fetal and maternal 
outcome among women undergoing 
vacuum extraction
SBR: 6/167 (3.6%).
PMR: 8/167 (4.8%).
Mesleh 2002 [136] Saudi Arabia.
Retrospective review. Vaginal 
deliveries (N = 304) with 
instrument use (N = 258 ventouse 
group, N = 46 forceps).
Assessed the effects of vacuum vs. 
forceps deliveries on pregnancy 
outcomes.
SBR: 1/258 vs. 0/46 in the forceps 
and ventouse groups, respectively.
The single stillbirth in the vacuum 
delivery group was due to 
intrapartum asphyxia and true knot 
in the umbilical cord.BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2393/9/S1/S6
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Emergency obstetric care, including Caesarean section
Background
The vast majority of the world's one million intrapartum
stillbirths each year occur in low-/middle-income coun-
tries marked by high rates of unmet obstetric need
[18,19], suggesting that many of these deaths could be
prevented with improved obstetric care [20,21]. The avail-
ability of comprehensive essential obstetric care (EOC),
supported by emergency transport, skilled providers, and
aftercare, is regarded as critical for effective maternal
health services in obstetric emergencies [22]. Essential
obstetric care (EOC) refers to elements of obstetric care
needed for the management of normal and complicated
pregnancy, delivery and the postpartum period. Basic
EOC can be performed in primary health care facilities,
and includes administration of anti-biotics, oxytocics,
anti-convulsants including magnesium sulfate, manual
removal of the placenta, treatment for incomplete miscar-
riage, post-abortion care, and instrumental vaginal deliv-
ery with forceps or vacuum extractor. Comprehensive
EOC includes all basic EOC functions plus Caesarean sec-
tion, anaesthesia, and blood transfusion, and generally
requires a secondary or higher-level health facility. The
subset of comprehensive EOC interventions used to
respond to unexpected intrapartum complications such as
haemorrhage and obstructed labour is referred to as emer-
gency obstetric care (EmOC) [23], and includes some ele-
ments of basic EOC such as manual removal of the
placenta and medical treatment in labour, as well as all
anaesthesia, blood transfusion, and Caesarean section.
Non-availability of EmOC, especially Caesarean section,
in resource-poor settings has been implicated as a risk fac-
tor for intrapartum stillbirths, particularly those associ-
ated with prolonged labour and its associated fetal
asphyxia, infection, and birth trauma [24-28]. Reductions
in intrapartum stillbirth rates observed in the UK have
been attributed to more liberal use of Caesarean section
[20], though this is controversial. There is evidence to sug-
gest that the optimal Caesarean section rate to reduce the
number and proportion of intrapartum stillbirths lies
between 5 and 10 percent [3]. Recent data from global
estimates of Caesarean section availability at population
level indicate that many countries fall far short of this
range, while others exceed this, to the possible detriment
of maternal health outcomes [29]. Some studies have
shown that it can be comparatively safe to deliver in rural
hospitals even if they lack Caesarean section capability
[30].
Quality of EmOC is also critical. These issues have been
documented in high-income countries, particularly
among rural populations [26,31,32], but the data associ-
ating quality of EmOC with stillbirth or perinatal mortal-
ity rates has not been compiled.
Because the components of EmOC are by definition life-
saving interventions, RCTs of EmOC versus no EmOC
would be unethical, so the evidence base for improving
access to and quality of EmOC, especially Caesarean sec-
tion, consists largely of observational studies.
Literature-based evidence
The literature on EmOC considered two primary issues:
availability and optimal rates of Caesarean section (and
associations with intrapartum stillbirth rates); and the
impact of quality of obstetric care on perinatal outcomes.
We identified 40 studies reporting stillbirth or perinatal
Results of new meta-analysis of impact of vacuum versus forceps delivery on stillbirths Figure 1
Results of new meta-analysis of impact of vacuum versus forceps delivery on stillbirths.
Study or Subgroup
Dell 1985
Ehlers 1974
Fall 1986
Lasbrey 1964
Mustafa R 2002
Portsmouth 1983
Stoke/Wigan
Total (95% CI)
Total events
Heterogeneity: Chi² = 0.40, df = 1 (P = 0.53); I² = 0%
Test for overall effect: Z = 0.47 (P = 0.64)
Events
0
0
0
1
0
0
0
1
Total
73
107
20
121
27
152
132
632
Events
0
0
0
1
1
0
0
2
Total
45
112
16
131
23
152
132
611
Weight
57.7%
42.3%
100.0%
Peto, Fixed, 95% CI
Not estimable
Not estimable
Not estimable
1.08 [0.07, 17.51]
0.27 [0.01, 7.02]
Not estimable
Not estimable
0.60 [0.07, 5.00]
Vacuum Forceps Odds Ratio Odds Ratio
Peto, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours controlBMC Pregnancy and Childbirth 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2393/9/S1/S6
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mortality outcomes that reviewed or implemented inter-
ventions to provide EmOC (Table 3).
Availability and practice of Caesarean section
In low-/middle-income countries, prolonged and/or
obstructed labour complicated by fetal asphyxia, fetal or
placental infection, and birth trauma is a major cause of
stillbirth, often arising from a small maternal pelvis due to
childhood malnutrition, which subsequently leads to
cephalopelvic disproportion during delivery [33]. Timely
delivery, often by Caesarean section or instrumental vagi-
nal delivery, can reduce associated intrapartum stillbirth,
and is largely credited for the relatively low rates of intra-
partum stillbirth in high-income countries [3].
Using regression analysis of data from WHO and other
sources to examine the association between stillbirth rates
and obstetric care, Goldenberg et al. [3] and McClure et al.
[21] observed that Caesarean section availability in low-/
middle-income countries was associated with reductions
in intrapartum stillbirths (Figures 2, 3 and 4). They [3]
reported that intrapartum stillbirths dropped by 1.61 per
1000 births for every one percentage point increase in
Caesarean section from 0 to 8 percent. Thereafter, they
observed a small, non-significant increase in intrapartum
stillbirths for each percent increase in Caesarean section.
Intrapartum stillbirth rates correlated more closely with
the measures of obstetric care in the regression analysis
than did antepartum stillbirth rates, corroborating the
theory that obstetric care availability and quality improve-
ments will impact intrapartum stillbirth incidence more
than antepartum stillbirth incidence. There was no rela-
tionship between Caesarean section and intrapartum still-
births in high-income countries, which all had rates of
Caesarean section of 15 percent or more. The WHO rec-
ommends Caesarean section rates of 10 to 15 percent,
although they also note that 'countries with some of the
lowest perinatal mortality rates in the world have a Cae-
sarean rate of less than 10 percent,' and that perinatal
mortality declines are steep until Caesarean section rates
reach approximately 8 percent of deliveries, after which
point the relationship becomes less clear [34]
Using data from the early 1980s in Australia, Alessandri et
al. [35] performed a case-control study of intrapartum
stillbirths, and could not identify any specific antenatal
risk factors that predicted these demises. However, they
did suggest that because the odds of emergency Caesarean
section were significantly higher among stillbirth cases
than live born controls, prompt Caesarean section might
reduce intrapartum stillbirths, the risk of which was
strongly associated with placental abruption or other pla-
cental problems, fetal distress, umbilical cord prolapse,
and vaginal breech delivery. Other studies have confirmed
that in many high-income country settings, liberal poli-
cies of Caesarean section are associated with positive
effects on fetal survival, even when performed well before
term [36-39].
While Caesarean section can be a life-saving intervention
for both mother and child, its liberal use exposes some
proportion of mothers and babies who do not need the
procedure to unnecessary risks of morbidity. Additionally,
in some low-/middle-income countries, particularly in
low-resource areas, there is some evidence that the prac-
tice of Caesarean section may be associated with an
increased  risk of perinatal mortality [40,41], suggesting
that Caesarean section may be performed too late or by
inadequately skilled practitioners in these settings. Addi-
tionally, the elevated risk of uterine rupture in subsequent
pregnancies after a Caesarean section should be a consid-
eration in providing the procedure in remote areas. In
addition to the risk of uterine rupture, the data are con-
flicting about whether vaginal labour after previous Cae-
sarean is associated with increased risk of perinatal
mortality [42-46]. Because of the known risk of uterine
rupture, particularly among women whose prior Caesar-
ean incision was classical rather than lower-segment, it is
recommended that women who have had prior classical
Caesarean section have immediate access to EmOC in
subsequent pregnancies to reduce the risk of maternal
mortality and stillbirth.
Quality of obstetric care
A number of studies associated suboptimal care, particu-
larly inadequate, inappropriate, or delayed care of com-
plications such as obvious fetal distress, placental
abruption, breech presentation, twin pregnancy, or
eclampsia, with increased perinatal mortality [47,48].
Several studies comparing hospitals or assessing health
systems found that quality of care provided in facilities
was directly associated with perinatal mortality [49-
51,25]. Recent improvements in term stillbirth rates, espe-
cially intrapartum stillbirths, suggest that more rapid per-
formance of Caesarean section in cases of placental
abruption has resulted in a lower incidence of abruption-
associated stillbirth [52]. In Virginia, USA, Cruikshank
and Linyear [53] observed that intrapartum stillbirths
associated with abruption were characterised by a fairly
long delay between the appearance of fetal compromise
and delivery, suggesting that timely Caesarean section
could have prevented these deaths. In Finland, Korhonen
and Kariniemi [54] found that having a surgical team in-
hospital to perform Caesarean sections versus having the
team on-call resulted in lower perinatal mortality (P =
0.05) and prevented all cases of fetal death and hypoxic
ischemic encephalopathy (versus 3/41 in controls and 1/
41 in controls, respectively).BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2393/9/S1/S6
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Table 3: Impact of emergency obstetric care on stillbirths and perinatal mortality
Source Location and Type of Study Intervention Stillbirths/Perinatal Outcomes
Quality and availability of obstetric care
Abdel-Latif et al; NICUS Group 
2006 [57]
Australia (New South Wales and 
Australian Capital Territory). 10 
neonatal intensive care units; 
stillbirth analysis done from other 
regional data.
Retrospective analysis. Infants (N 
= 8654) < 32 wks' gestation born 
1992–2002 (N = 1879 rural areas, 
N = 6775 urban). Regional SB 
analysis: N = 14,707 births.
Compared the impact of rural vs. 
urban residence and associated 
differentials in access to higher-
level emergency obstetric care on 
perinatal mortality measures.
NMR (in NICU): adj. OR = 1.26 
(95% CI: 1.07–1.48, P = 0.005) in 
rural vs. urban group.
SBR: OR = 1.20 (95% CI: 1.09–
1.32; P < 0.001).
[727/3530 (20.6%) vs. 1991/11177 
(17.8%) in rural and urban infants, 
respectively].
Cameron 1998 [25] Australia (Far North Queensland). 
Atherton Hospital.
Descriptive study. N = 2883 
deliveries from 1981–1990 (N = 
1974 public confinements, N = 909 
private confinements).
Assessed annual obstetric audit 
data from 1981–1990 to compare 
publicly versus privately funded 
facilities.
PMR: 5.1/1000 vs. 5.5/1000 in 
public and private confinements, 
respectively.
PMR (corrected): 9.6/1000 vs. 
13.5/1000 vs. 16.9/1000 in public 
patients, Queensland (1987) and 
the Far North Statistical Division 
(1987), respectively.
Gaffney et al. 1994 [48] UK (Oxford). National Perinatal 
Epidemiology Unit.
Case control study. N = 573 
participants, of whom N = 141 
cerebral palsy group (N = 257 
controls) and N = 62 perinatal 
deaths (N = 119 controls).
Compared the frequency of events 
during labour and delivery, and the 
suboptimal care among cases (with 
perinatal deaths) vs. controls.
Intrapartum haemorrhage: OR = 
5.3 (95% CI: 1.4–20.1) in cases of 
deaths vs. controls.
Meconium stained amniotic fluid: 
OR = 12.3 (95% CI: 3.6–41.4) in 
cases of deaths vs. controls.
Failure to respond to signs of 
severe fetal distress: OR = 26.1 
(95% CI: 6.2 – 109.7) in cases of 
deaths vs. controls.
Goldenberg et al. 2007 [3] Review. Data from 51 countries 
(WHO and other sources).
Logistic regression analysis of 
measures of antenatal and 
obstetric care with perinatal 
outcomes.
Intrapartum SB: for each 1% 
increase in the percentage of 
women with at least 4 antenatal 
visits, the intrapartum SBR 
decreased by 0.16/1000 births (P < 
0.0001).
Intrapartum SB: as Caesarean 
section rates increased from 0 to 
8%, for each 1% increase, the 
intrapartum SBR decreased by 
1.61/1000 births. No relationship 
between Caesarean section and 
SBR in high-income countries.
Stronger relationship between 
various measures of care with 
intrapartum versus antepartum 
SBR.
Grzybowski et al. 1991 [59] British Columbia (Queen 
Charlotte Islands). 21-bed hospital 
and medical clinic.
Descriptive study. All women (N = 
286) >20 wks' gestation delivering 
from 1984–88. 33% were 
primiparous, 20% native. N = 192 
(67%) delivered locally, N = 33 
(12%) transferred after admission 
for complications, N = 61 (21%) 
delivered elsewhere.
Assessed the PMR among women 
delivering at a small hospital 
without Caesarean section 
capability delivering <50 infants 
per year.
PMR: 20.8 (95% CI: 4.4–37.2); N = 
6.
Adverse perinatal outcome: 6.2% 
(12/193 newborns) (95% CI: 2.8–
9.6%).BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2393/9/S1/S6
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Kiely et al. 1985 [56] USA (New York City).
Prospective study. All births of 
infants weighing > 1000 g from 
1976–78.
Computed fetal mortality rates 
(adjusted for confounding by birth 
weight, gestational age, and other 
variables) at different levels of 
care.
Intrapartum SBR: 61% excess risk 
in Level 1 (community hospital) vs. 
Level 3 (perinatal intensive care) 
maternity units)(P > 0.01).
Intrapartum SBR: 35% excess risk 
in Level 2 units (intermediate level 
of care) vs. Level 3 units (P = 0.06).
Korhonen and Kariniemi 1994 [54] Finland.
Prospective study. Cases of 
emergency Caesarean section (N 
= 101). N = 60 cases study group, 
N = 41 controls.
Compared the impact on survival 
of cases with the operating team in 
the hospital (study group) vs. cases 
with the team on call (outside the 
hospital) (controls).
Live birth/neonatal survival rate: 
significantly higher when the 
operating team was in the hospital 
vs. on call outside the hospital), P 
= 0.05. SBR: 0/60 vs. 3/41 in 
intervention vs. controls, 
respectively
. 
Hypoxic ischemic encephalopathy: 
1/41 in the controls.
Lansky et al. 2007 [50] Brazil (Belo Horizonte). 
Population-based in 24 hospitals.
Cohort study. N = 36,469 births, 
N = 419 perinatal deaths in 1999.
Compared PMR in hospitals 
contracted to the National Public 
Health System (SUS) with non-SUS 
hospitals.
PMR: OR = 2.92 (95% CI: 1.87–
4.54) in the private-SUS vs. private 
non-SUS hospitals.
PMR: OR = 1.81 (1.12–2.92) in the 
philanthropic-SUS vs. private non-
SUS hospitals.
PMR: OR = 1.30 (95% CI: 0.82–
2.05) [NS] in the public SUS vs. 
private non-SUS hospitals.
Lansky et al. 2007 [49] Brazil (Belo Horizonte).
Cohort study. N = 40,953 births 
and N = 826 perinatal deaths in 
1999.
Compared PMR in hospitals linked 
to the national Universal Public 
Health System (SUS) vs. non-SUS 
hospitals.
PMR: highest in private and 
philanthropic SUS-contracted 
hospitals relative to private, non-
SUS-contracted hospitals.
Quality of care also associated 
with PMR.
Leeman et al. 2002 [30] USA (New Mexico). Native 
American hospital.
Retrospective cohort study. All 
pregnant women (N = 1132) > 20 
weeks gestation 1992–1996. N = 
735 (64.7%) gave birth at the 
hospital without operative 
facilities; N = 290 (25.6%) were 
transferred before labour; and N = 
107 (9.5%) were transferred 
during labour.
Compared the PMR at hospital 
lacking on-site Caesarean 
capability but with a high-risk 
obstetric population) with the 
nationwide PMR (historical 
controls).
PMR: 11.4/1000 (95% CI: 5.1–17.8) 
vs. 12.8/1000 at the hospital vs. 
nationwide, respectively [NS].
Caesarean section rate: 7.3% vs. 
20.7% at the hospital and 
nationwide, respectively 
(statistically significant).
Low Apgar score: 0.54% vs. 1.4% 
at the hospital and the nationwide, 
respectively (statistically 
significant).
Resuscitation required: 3.4% vs. 
2.9% at the hospital and 
nationwide, respectively [NS].
Longombe et al. 1990 [41] Zaire. Rural setting.
Retrospective study. Total 
deliveries (N = 9947) during a five-
year period. N = 8476 (85.2%) 
normal deliveries; N = 1014 
(10.2%) Caesarean; N = 484 (4.9%) 
complicated vaginal deliveries.
Compared the impact on perinatal 
mortality in the Caesarean group 
(study group #1) vs. complicated 
vaginal deliveries (study group #2) 
vs. normal deliveries (comparison 
group).
PMR: 3.67% vs. 2.29% vs. 0.75% in 
study group #1, study group #2, 
and comparison group, 
respectively.
McClure et al; NICHD FIRST 
BREATH Study Group 2007 [137]
Democratic Republic of Congo, 
Guatemala, India, Zambia, Pakistan, 
Argentina. Population-based study, 
community-based.
Prospective cohort study. N = 
60,324 deliveries over an 18-
month period.
Assessed care-based risk factors 
for SBR in different low-/middle-
income countries.
SBR: 34/1000 vs. 9/1000 in 
Pakistan and Argentina, 
respectively.
Maceration: 17.2% of stillbirths.
Higher SBR significantly associated 
with less-skilled providers, out-of-
hospital births, and low Caesarean 
section rates.
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Rautava et al. 2007 [51] Finland. 14 level II (central) and 5 
level III (university) hospitals.
Retrospective national medical 
birth-register study. N = 2291 very 
pre-term infants (gestational age 
<32 weeks at birth or birth weight 
of ≤ 1500 g) born from 2000–
2003.
Compared PMR between level II 
(central) and level III (university) 
hospitals.
IMR + SBR: 494/2291 infants 
(21.6%).
IMR: 224/2021 (11.1%) among live-
born infants.
Both the total 1-year mortality and 
the 1-year mortality of live-born 
infants were higher in level II 
hospitals compared with level III 
hospitals.
Steyn et al. 1998 [58] South Africa. Hospital records.
Retrospective analysis. N = 
174,713 deliveries during 1975–
1994), of which N = 22,773 were 
by Caesarean.
To describe trends in Caesarean 
section and PMR over the study 
period.
PMR: 34.7/1000 vs. 18.4/1000 in 
1975 vs. 1994, respectively.
The Caesarean section rate stayed 
constant at about 13% during this 
period.
Practice of Caesarean section and impact on perinatal mortality
Bottoms et al. 1997 [37] USA. Academic referral centers 
with neonatal intensive care units.
Prospective observational study. 
Singleton extremely low birth 
weight (LBW) infants (N = 713) 
over a one-year study period (N = 
482 study group, N = 231 
controls).
Compared the impact on PMR of 
provider willingness to perform 
Caesarean delivery at 24 weeks for 
indications of fetal distress 
(intervention) vs. provider 
unwillingness to provide early 
Caesarean for these indications 
(controls).
Neonatal survival: adj. OR = 3.7 
(95% CI: 2.3–6.0); P = 0.0001 in 
the study vs. control group, 
respectively.
Survival without serious neonatal 
morbidity: OR = 1.8 (94% CI: 1.0 = 
3.3) [NS] in the study vs. control 
group, respectively.
SB: 19.5% vs. 0% for 21 weeks vs. 
> 28 weeks, respectively.
NMR: 78% vs. 3.3% in 21 weeks 
and 30+ weeks, respectively.
De Muylder and Amy 1993 [40] Zimbabwe (the Midlands 
Province). 12 hospitals.
Prospective study. Deliveries from 
1985–1986 in 12 hospitals (N = 
19,363 deliveries/year), with 
Caesarean section rates ranging 
from 2.2–16.8%.
To assess the impact of high versus 
low Caesarean section rates on 
perinatal outcome.
PMR: 51.9/1000 vs. 39.7/1000 
births in 6 hospitals with high rate 
of Caesarean section vs. 6 
hospitals with high rate of 
instrumental delivery, respectively. 
Statistically significantly higher in 
hospitals with 
instrumental:Caesarean section 
ratio < 0.2.
Caesarean section and PMR 
positively correlated: R2 = 0.429 (P 
= 0.021).
Hankins et al. 2006 [36] USA.
Review.
To assess the impact on neonatal 
morbidity and mortality in a high-
income country setting of allowing 
women to opt for delivery by 
elective Caesarean section at 39 
weeks of gestation.
Extracted findings from reviewed 
studies:
SBR: steady from 23–40 wks 
gestation, 5% of all stillbirths 
occurring at each week of 
gestation (Copper).
SBR: 0.6/1000 vs. 1.9/1000 live 
births at 33–39 wks vs. >39 wks' 
gestation (Yudkin).
SBR: 1.3–4.6/1000 live births from 
37–41 wks' gestation (Fretts).
Estimated prevention of SB 
associated with elective Caesarean 
for all births at 39 wks: 2/1000 
living fetuses (6000 SBs prevented 
in the US each year).
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Iffy et al. 1994 [38] Ireland (Dublin) and USA 
(Newark, New Jersey). 2 large 
hospitals.
Observational study. N = 68479 
births (excluding malformations). 
Caesarean section rates: 6% in 
Ireland hospital, 17.5% at USA 
hospital.
Compared the PMR associated 
with different Caesarean section 
rates at 2 different hospitals.
PMR: 611/50768 (12.0/1000) vs. 
343/17711 (19.8/1000) in Newark 
vs. Dublin, respectively; P < 0.01.
NMR: No impact.
Ilesanmi et al. 1996 [47] Nigeria (Ibadan). Oluyoro Catholic 
Hospital.
Descriptive study. Breech 
singleton deliveries (N = 441 of 
21,243 deliveries).
Compared the intrapartum 
stillbirth rate associated with 
breech (study group) vs. cephalic 
deliveries (controls).
Fresh SBR: 7.8% vs. 1.2% for 
breech and cephalic, respectively 
over the same time period.
Caesarean section performed for 
15.7% of breech singleton 
deliveries (indicatioN = fetal 
distress).
McClure et al. 2007 [21] 188 developed and developing 
countries. WHO data.
Regression analysis.
To analyze correlation between 
SBR and multiple measures of 
antenatal and obstetric care 
(Caesarean section rates, skilled 
delivery attendance, and complete 
ANC).
SBR and MMR: strongly correlated, 
~5 SBs for each maternal death. 
Ratio: 2:1 in least developed 
countries vs. 50:1 in the most 
developed countries.
SBR: Decreased sharply as 
Caesarean section rates increased 
from 0 to about 10%, (same for 
MMR).
SBR: No significant reductions 
associated with skilled attendance 
until coverage rates ~40%.
SBR: No reductions associated 
with complete ANC until 60% 
coverage was achieved (modest 
reduction).
Mekbib and Teferi 1994 [138] Ethiopia (Addis Ababa). Hospital-
based study.
Retrospective review of hospital 
records. N = 11,657 consecutive 
deliveries 1987–1992). N = 645 
Caesarean sections (5.5%).
Compared the impact PMR of 
deliveries by Caesarean section vs. 
all deliveries (controls).
PMR: 153.5/1000 (N = 99) vs. 
67.5/1000 live births in Caesarean 
section group vs. rate for all 
deliveries respectively (P < 0.01).
O'Driscoll et al. 1988 [39] USA (Dallas, TX) and Ireland 
(Dublin).
Retrospective analysis of hospital 
records from 1982–84. Pregnant 
women admitted to hospital (N = 
24441 at Dublin; N = 22580 
women in Dallas).
Compared the impact on PMR 
between a low Caesarean section 
rate hospital (Dublin) vs. a high 
Caesarean section rate hospital 
(Dallas).
CS rates: 482/8068 (6.0%) vs. 
2001/10988 (18.0%) in Dublin vs. 
Dallas, respectively in 1983.
[330/7782 (4.2%) vs. 2022/11592 
(17.3%) in Dublin vs. Dallas, 
respectively in 1984.]
PMR: 148/8199 (17.9/1000) vs. 
161/11098 (14.5/1000) in Dublin 
vs. Dallas, respectively in 1983.
[119/7879 (15.1/1000) vs. 207/
11716 (17.8/1000) at Dublin and 
Dallas, respectively in 1984.]
Intrapartum SB: 7-fold lower in 
Dallas compared to Dublin in 
1983. Including 1982 & 1984, no 
significant difference in overall 
PMR despite 4 times as many 
Caesareans in Dallas as Dublin.
Wright et al. 1991 [139] Nigeria. Jos University Teaching 
Hospital (high-risk population).
Descriptive study. N = 757 
patients undergoing Caesarean 
section.
Assessed PMR among a case series 
of Caesarean section.
PMR: 235/1000 (N = 69 stillbirths 
and N = 107 early neonatal 
deaths).
Caesarean section rate: 4.4%.
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Management of risk factors for stillbirth
Abate et al. 2006 [140] Ethiopia (Addis Ababa). Two 
teaching hospitals.
Retrospective study. Eclamptic 
cases (N = 216) diagnosed, 
admitted and managed from 
October 1994 to September 1999.
To assess the stillbirth rate (SBR) 
and perinatal mortality rate (PMR) 
among women admitted to 
hospital who presented with or 
who developed eclampsia.
SBR: 44/216.
Early neonatal deaths: 25/216.
PMR: 312.2/1000 deliveries.
Alessandri et al. [35] Australia (Western Australia).
Matched case-control study. 
Intrapartum stillbirths ≥1000 g 
(cases) and live born infants 
(controls) matched for year of 
birth (1980–1983), plurality, sex, 
birth weight, and race of mother.
To determine antenatal and 
intrapartum risk factors for 
intrapartum stillbirths at the 
population level.
Placental abruption: OR = 9.55 
(95% CI: 2.09–43.69) in cases 
versus controls, respectively.
Fetal distress: OR = 4.64 (95% CI: 
1.92–11.19) in cases versus 
controls, respectively.
Cord prolapse: OR = 10.00 (95% 
CI: 1.17–85.60)
Placental problems (OR = 2.26, 
95% CI: 1.13–4.52)
Vaginal breech delivery: OR = 3.51 
(95% CI: 1.40–8.80) and
Emergency Caesarean section: OR 
= 2.15 (95% CI: 1.13–4.10).
No antenatal risk factors predicted 
deaths.
Basso et al. 2006 [141] Norway. Population-based using 
data from the Medical Birth 
Registry.
Longitudinal study. Singleton 
firstborn fetuses (N = 804,448) 
with Norwegian-born mothers 
born 1967–2003.
Compared the impact on perinatal 
outcomes of being born to 
preeclamptic (exposed) vs. non-
preeclamptic (unexposed) 
mothers in the period from 1991–
2003 vs. 1967–1978.
SBR: OR = 1.3 (95% CI: 1.1–1.7) in 
exposed vs. unexposed group, 
respectively from 1991–2003 vs. 
adj. OR = 4.2 (95% CI: 3.8–4.7) in 
exposed vs. unexposed group 
from 1967–78.
Induction before 37 weeks for 
preeclampsia: 20% vs. 8% in 1991–
2003 vs. 1967–78, respectively.
Bhattacharyya et al. 1979 [142] India.
Prospective study. Patients (N = 
60) with previous stillbirths. A 
majority (75%) had a history of 
repeated stillbirths, and 
responsible pathology was 
detected in 55% of the cases.
To assess the impact of active 
antepartum, intrapartum, and early 
postnatal care in women with 
previous stillbirths.
Live birth: 75%.
Cruikshank and Linyear 1987 [53] USA (Virginia).
Perinatal audit. N = 108 term fetal 
deaths in 1983.
Assessed circumstances and 
management of term fetal deaths 
occurring in Virginia to determine 
potential preventability.
Preventable fetal death: 52/108 
(48%)
Risk factors for antepartum fetal 
death: maternal hypertension, 
diabetes, inadequate fetal 
surveillance, post-term pregnancy
Major cause of intrapartum fetal 
death: delay between obvious fetal 
compromise onset and delivery.
Incidence of preventable term 
stillbirth lower in larger hospitals.
Onyiriuka 2006 [143] Nigeria (Benin City).
Retrospective, observational 
study. All babies born weighing > 
4000 g.
Compared the fetal outcome in 
high birth weight babies (study 
group) vs. normal weight babies 
(controls).
Risk of fetal death higher in high 
birth weight babies (full text not 
available).
Risk of Caesarean section higher in 
high birth weight babies (full text 
not available).
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Management and mortality of twin delivery, including impact of Caesarean section
Ananth et al. 2004 [144] USA.
Retrospective cohort study. Twin 
live births and stillbirths between 
1989–91 and 1997 = 99 (N = 
1,102,212).
Compared the changes in the SBR 
(≥22 weeks), labour induction, and 
Caesarean rates among twin births 
from 1989–91 and 1997–99.
SBR: RR = 0.52 (95% CI: 0.49–
0.55) [13.9/1000 vs. 24.4/1000 in 
1999 vs. 1989, respectively (48% 
decrease).]
SBR excluding births weighing < 
500 g and adjusting for changes in 
labour induction and Caesarean 
delivery: RR = 0.75 (95% CI: 0.72–
0.79)(25% decrease).
Labour induction: 13.8% vs. 5.8% in 
1997–99 vs. 1989–91, respectively 
(138% increase).
Caesarean delivery: 55.6% vs. 
48.3% in 1997–99 vs. 1989–91, 
respectively (15% increase).
Fakeye 1988 [145] Nigeria (Ilorin). University of Ilorin 
Teaching Hospital.
Descriptive study. Consecutive 
twin pairs (N = 622). N = 146 
twin-1 and N = 192 twin-2 breech 
births.
Compared PMR between first and 
second twin breech infants.
SB and asphyxia (Apgar 1,2, or 3) 
high in both first and second twin 
breech infants.
PMR: 13.7% vs. 18.8% for twin-1 
and twin-2 breech, respectively.
Corrected PMR: 9.3% vs. 12.4% 
for twin-1 and twin-2 respectively 
among infants weighing 2.0 kg or 
more. Twin-specific breech PMR 
lowest in 2.5–2.9 kg group (higher 
for smaller and larger twins).
Breech-breech or primary breech 
managed by Caesarean section: 
lower PMR than vaginally delivered 
breech twin pairs.
Rydhstrom and Ingemarsson 1991 
[146]
Sweden (Stockholm). The National 
Medical Birth Registry.
Matched case-control twin study. 
N = 273 twin pregnancies 
delivered 1973–1983 weighing 
1500–2499 g. N = 91 pregnancies 
(cases), N = 182 controls.
To compare the Caesarean section 
rates between the cases where 
one or both twins died vs. controls 
with similar birth weight (+/- 100 
g) and year of delivery (+/- 1 year).
Caesarean section rate: 20% vs. 
50–65% in 1973–76 vs. 1981–83 
respectively, with an increase for 
both cases and controls. No 
significant difference between 
groups [NS]
Smith et al. 2005 [147] UK (Scotland).
Retrospective cohort study. All 
twin births (N = 8073) ≥36 weeks 
of gestation, excluding antepartum 
stillbirths and perinatal deaths due 
to congenital abnormality, 1985–
2001; of which N = 1472 deliveries 
by planned Caesarean section.
To determine PMR among twins 
born at term in relation to mode 
of delivery.
PMR (2nd twin vs. 1st): OR = 5.00 
(95% CI: 2.00–14.70)
[6 vs. 30 deaths in first vs. second 
twins, respectively].
PMR (either twin): OR = 0.26 
(95% CI: 0.03–1.03) [NS].
[2/1472 (0.14%) vs. 34/6601 
(0.52%) deliveries in either twin by 
planned Caesarean section vs. 
other means, respectively; P = 
0.05]. No association of birth 
order and PMR among those 
delivered by planned Caesarean 
section.
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Smith et al. 2007 [148] UK (England, Northern Ireland and 
Wales).
Retrospective cohort study. N = 
1377 twin pregnancies with one 
twin dying perinatally (excluding 
malformations) and one surviving, 
1994–2003.
To assess PMR based on birth 
order in twin pregnancies.
Birth order and the risk of death 
overall: OR = 1.0 (95% CI: 0.9–1.1) 
for the second twin [NS].
However, there was a highly 
significant interaction with 
gestational age (P < 0.001).
PMR among 2nd twins born at 
term: OR = 2.3 (95% CI: 1.7–3.2, P 
< 0.001). Higher risk for vaginal 
birth (OR = 4.1, 95% CI: 1.8 to 
9.5) compared with Caesarean 
section (OR = 1.8, 95% CI: 0.9 to 
3.6); P = 0.10.
PMR among 2nd twins at term 
associated with intrapartum anoxia 
or trauma (OR = 3.4, 95% CI: 2.2 – 
5.3).
VBAC vs. repeat Caesarean section
Bahtiyar et al. 2006 [149] USA. Perinatal mortality data 
(1995 to 1997).
Cross-sectional study. Deliveries 
of singleton term pregnancies (N = 
11,061,599) in women 15–44 years 
collected 1995–97. Caesarean 
delivery rate was 19.6%.
Compared the impact on SBR 
among pregnant women with a 
prior Caesarean delivery 
(intervention) vs. women with no 
prior Caesarean delivery (control).
Crude fetal death 
(miscarriage+SB): 1.3/1000 vs. 1.5/
1000 births in intervention vs. 
control groups, respectively.
Adjusted fetal death 
(miscarriage+SB): 0.4/1000 vs. 0.6/
1000 births in intervention vs. 
control groups, respectively.
Subset of women with only 1 prior 
delivery:
Fetal death (miscarriage+SB): RR = 
0.90 (95% CI: 0.76–1.06) [NS].
[0.7/1000 vs. 0.8/1000 births in 
intervention vs. control groups, 
respectively].
Kumar et al. 1996 [42] Western Australia.
Retrospective study. Women (N = 
79) with prior Caesarean section. 
N = 33 (41.8%) women agreed to 
a trial of vaginal birth. N = 29 
women had labour induced and 26 
(89.7%) of them had a successful 
vaginal delivery.
To assess the PMR in women 
attempting vaginal birth after 
Caesarean section (VBAC).
PMR: 0/79.
Vaginal delivery rate: 87.9% in 
women undergoing a trial of 
vaginal birth.
Caesarean section for fetal 
distress: 4/33 (12.1%).
Caesarean section rate: fell from 
32.2% to 11% in hospital during 
the study period.
Meehan et al. 1989 [43] Ireland (Galway). Regional 
Hospital.
Retrospective analysis. N = 27,072 
babies born 1972–1982. N = 1498 
patients with prior Caesarean 
section, including N = 654 (44%) 
with repeat elective Caesarean 
section and N = 844 (56%) with 
VBAC.
Compared the impact on PMR 
among women with prior 
Caesarean section according to 
the mode of delivery: elective 
Caesarean section, VBAC, and 
emergency Caesarean section).
PMR: 30.3/1000 (N = 46) vs. 22.5/
1000 in all women with prior 
Caesarean section vs. overall 
hospital population, respectively.
PMR: 10.6/1000 vs. 90.3/1000 in 
those delivered by elective 
Caesarean section vs. those by 
emergency Caesarean section 
(statistically significant)
Successful vaginal delivery 
occurred in 702 (83%) patients and 
142 (17%) had emergency repeat 
operations. Corrected PMR was 
twice as high in the trial of scar 
group.
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Mock et al. 1991 [45] West Africa. Rural hospital based.
Descriptive study. Women (N = 
220) with prior Caesarean section 
delivering 1987–1990. N = 169 
patients given a trial of labour, of 
whom vaginal delivery was 
achieved in 111 (66%).
Compared the impact on maternal 
and fetal outcome between 
women given a trial of labour and 
those given elective repeat 
Caesarean section.
PMR: [NS]
Nyirjesy et al. 1992 [44] Northeastern Zaire. Rural referral 
hospital.
Descriptive study. Women (N = 
33) with previous Caesarean given 
trial of labour in 1989–1990, of 
which 22 (67%) had successful 
vaginal deliveries.
Assessed the PMR in women given 
a trial of labour (study group) vs. 
the overall rate for the institution 
(controls).
PMR: 60.1/1000 (study group) 
[NS] compared to controls.
van Roosmalen 1991 [46] Tanzania. 2 rural hospitals.
Observational study. N = 134 
women with a history of previous 
Caesarean section, of which N = 
87 had a vaginal delivery after a 
trial of labour.
Compared PMR in women with a 
previous Caesarean birth in 
relation to the indication of the 
previous operation, a history of 
previous vaginal delivery and the 
number of previous operations.
PMR: 9/64 (14%) vs. 4/45 (9%) vs. 
0/25 (0%) where the indication for 
previous Caesarean was CPD vs. 
nonrecurrent vs. unknown, 
respectively [NS].
PMR: 3/43 (7%) vs. 10/91 (11%) in 
women without previous vaginal 
birth vs. with previous vaginal 
respectively [NS].
PMR: 10/114 (9%) vs. 3/20 (14%) in 
women with one previous 
Caesarean vs. more than one 
Caesarean, respectively [NS].
Table 3: Impact of emergency obstetric care on stillbirths and perinatal mortality (Continued)
Jehan et al. [55] recently reviewed stillbirths in rural Sindh
Province, Pakistan, and found that a large proportion of
these stillbirths occurred in facility settings with ostensi-
bly skilled care providers. Because the rate of fetal mortal-
ity in labour seems to be reduced with adequate care, Kiely
et al [56] have proposed using fetal deaths in labour as an
epidemiologic measure of the quality of obstetric care.
They found that delivery in a level 1 (primary care) hospi-
tal was associated with a 60% increase in intrapartum still-
birth compared to a level 3 facility (equipped for perinatal
intensive care). Similarly, a retrospective analysis [57]
found that rural residence was associated with elevated
stillbirth rates (OR = 1.20; 95% CI: 1.09–1.32, P < 0.001)
and neonatal death in hospital (adjusted OR = 1.26; 95%
CI: 1.07–1.48) compared to urban residence, which
granted women better access to higher-level emergency
obstetric care.
There is some limited evidence that Caesarean section
capability is not the only component of EmOC with the
potential to reduce perinatal mortality. Advances in
labour management and perinatal care have also contrib-
uted to significant declines in perinatal mortality. Steyn et
al [58] observed that over a 20-year period in South Africa,
the Caesarean section rate remained constant, but perina-
tal mortality decreased by 50 percent. In a remote area of
the US in a high-risk Native American obstetric popula-
tion, Leeman et al [30] documented a Caesarean section
rate one-third of the national average without any adverse
impact on perinatal mortality rate (PMR), which was the
same as the national average. Even in remote areas with-
out Caesarean section capability, intrapartum stillbirths
and perinatal deaths can be significantly reduced with
improved quality of obstetric and perinatal care alone.
Source: Goldenberg et al. 2007 Figure 2
Source: Goldenberg et al. 2007.
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Source: McClure et al. 2007 Figure 4
Source: McClure et al. 2007.
Relationship between Cesarean sections and intrapartum  stillbirths Figure 3
Relationship between Cesarean sections and intra-
partum stillbirths. Source: Goldenberg et al. 2007.
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Grzybowski [59] undertook a prospective study to deter-
mine whether a small, isolated hospital without Caesar-
ean section capability and which handled fewer than 50
births annually could provide safe obstetric and perinatal
care. Over the 5-year study period, there were 6 perinatal
deaths, for a perinatal mortality rate of 20.8 per 1000
(95% CI: 4.4–37.2 per 1000); however, the wide confi-
dence intervals indicate the study was underpowered to
measure perinatal mortality, and the perinatal mortality
rate was still more than double that of many high-income
countries, including the US [60].
Conclusion
While varied in design and lacking the rigor of RCTs, evi-
dence from available, largely observational studies, taken
together, indicates that availability of facilities capable of
providing EmOC with trained care providers who are able
to undertake safe and timely Caesarean section for appro-
priate indications is critical for reducing the risk of intra-
partum stillbirths. It is not possible, however, based on
the available data to ascertain the relative contribution of
various components of EmOC to the mortality reductions
observed. The need for Caesarean section capacity in rural
settings is apparent from the data. The risk of uterine rup-
ture and placental invasion of the uterine scar, and the
higher rate of stillbirth in subsequent pregnancies after
Caesarean section [61] suggests that liberal Caesarean sec-
tion policies are unjustifiable, especially where access to
emergency obstetric care is limited or home birth is com-
mon. Medically unnecessary Caesarean sections would
place a large group of women at risk of uterine rupture if
they do not or cannot access EmOC in subsequent preg-
nancies. A Caesarean section rate of 10–15% as recom-
mended by WHO appears appropriate, particularly in
resource-constrained settings; it is paramount that the
procedure is performed for indications of fetal distress or
other standard indications, rather than for the conven-
ience of the provider or on maternal request. Additionally,
several studies reported significant improvement in peri-
natal mortality rates in facilities without Caesarean sec-
tion capability, and others demonstrated that Caesarean
section provided too late or in too remote a setting
increased perinatal mortality, suggesting that quality of
obstetric care, rather than mere availability of Caesarean
section, is key in preventing stillbirths and perinatal
deaths. Despite the obvious lack of RCTs, the evidence in
support of increased emergency Caesarean section availa-
bility to reduce stillbirths is strong (Grade B); EmOC is
needed in all low-/middle-income country health sys-
tems.
Induction of labour (versus expectant management)
Background
Induction of labour, a common intervention in obstetric
practice, is indicated when it is determined that the fetus
or mother will more likely have a healthy outcome than if
birth is delayed. While many studies have compared dif-
ferent regimens and administration techniques of drugs to
ripen the cervix and induce labour, few have evaluated the
outcomes associated with induction versus expectant
management of spontaneous labour for different indica-
tions [62]. Induction is frequently practised at term or
post-term, or in cases in which the fetus is suspected to be
macrosomic and therefore likely to require complicated
operative delivery [63]. Additional common indications
for induction of labour include pre-eclampsia, cases of
premature rupture of membranes (PROM) where labour
does not quickly become spontaneously established
thereafter, and twin pregnancy. The process of induction
of labour should only be considered when vaginal deliv-BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2393/9/S1/S6
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ery is felt to be the appropriate route of delivery. Many dif-
ferent agents and methods can be used to induce and
augment labour, including drugs such as oxytocin or pros-
taglandins, and physical interventions including sweep-
ing the membranes or early amniotomy. Little is known
about the impact of induction for different indications on
stillbirth and perinatal outcomes.
Literature-based evidence
Our literature search identified 5 Cochrane reviews and 3
other interventional/observational studies (Table 4).
Post-term pregnancy/prevention of obstructed labour due to cephalo-
pelvic disproportion
Considering the merits of induction in post-term preg-
nancies, Gülmezoglu et al. [64] reported a non-significant
reduction in stillbirth risk (RR = 0.28, 95% CI: 0.05–1.67,
12 trials, N = 5939 women), but a statistically significant
reduction in perinatal mortality (RR = 0.30, 95% CI:
0.09–0.99, 12 trials, N = 5939 women), in induced versus
expectantly managed groups [LOE: 1+] (Additional file
3).
Irion et al. [63] (Additional file 4) reviewed three trials
involving 372 non-diabetic women who underwent
induction of labour for suspected fetal macrosomia. Com-
pared to expectant management, induction of labour for
suspected macrosomia did not reduce risk of Caesarean
section (RR = 0.96, 95% CI: 0.67–1.38) or instrumental
delivery (RR = 1.02, 95% CI: 0.60–1.74) [LOE: 1++].
Boulvain et al. [65] (Additional file 5) conducted a review
of elective delivery, either by induction of labour or by
elective Caesarean section, compared to expectant man-
agement, and included one trial [66] which compared a
policy of active induction of labour at 38 weeks to expect-
ant management until 42 weeks. The risk of Caesarean
section was not statistically different between groups (RR
= 0.81, 95% CI: 0.52–1.26), but the risk of fetal macro-
somia was reduced in the active induction group (RR =
0.56, 95% CI: 0.32–0.98). No other perinatal morbidity
was reported [LOE: 1-].
Premature rupture of membranes (PROM)
Dare et al. [67] conducted a Cochrane review to assess the
effects of induction of labour versus expectant manage-
ment among women with premature rupture of mem-
branes (PROM) at term (12 RCTs, N = 6814 women)
(Additional file 6). They found that planned management
generally involved induction with oxytocin or prostaglan-
din; one trial used homoeopathic caulophyllum. Signifi-
cantly fewer women in the induced compared with the
expectant management groups developed chorioamnio-
nitis (RR = 0.74, 95% CI: 0.56–0.97; 9 trials, 6611
women) or endometritis (RR = 0.30, 95% CI: 0.12 to 0.74;
4 trials, 445 women). There was a non-significant trend
toward lower perinatal mortality (OR [fixed]: 0.46, 95%
CI: 0.13–1.66) and neonatal infection incidence (RR =
0.83, 95% CI: 0.61–1.12; 9 trials, 6406 infants) in the
induced versus the expectantly managed groups. There
was no difference between the two groups in Caesarean
section rates (12 trials, N = 6814 women, RR = 0.94, 95%
CI: 0.82–1.08) or operative vaginal birth (7 trials, N =
5511 women, RR = 0.98, 95% CI: 0.84–1.16) [LOE: 1+].
Another Cochrane review on induction of labour for pre-
term PROM (prior to 37 weeks of gestation) is in progress
[68]. An intervention study from Brazil [69] not included
in the above Cochrane review reported no difference in
fetal deaths among a group of women with PROM at term
(N = 150) given vaginal misoprostol vs. those managed
expectantly for 24 hours, then given intravenous oxytocin
[LOE: 1+].
Multiple pregnancy
Dodd et al. [70] investigated the optimal timing of elec-
tive induction of labour after 37 weeks in twin pregnancy
(N = 72 women) and reported no statistically significant
differences between a group electively induced at 37
weeks versus an expectantly managed group; the study
was underpowered to detect true differences in perinatal
mortality rates [LOE: 1-] (Additional file 7).
Grand multiparity
Several other intervention and observational studies not
included in the Cochrane reviews addressed the impact of
induction of labour on perinatal outcomes. In Saudi Ara-
bia among a group of grand multiparas at term, Chatto-
padhayay et al. [71] reported a lower stillbirth rate in a
group receiving intracervical prostaglandin E2 tablets
compared to a group in which labour was managed
expectantly (SBR: 0/150 vs. 4/150 in prostaglandin versus
expectantly managed groups, respectively; no statistical
significance data given).
New meta-analysis
We conducted a meta-analysis of trials (3 RCTs, N = 1770
women) of planned induction of labour using prostaglan-
dins versus expectant management in women with
PROM. No significant decrease in perinatal mortality was
found (OR = 0.50, 95% CI: 0.05–5.53) in the planned
induction versus expectantly managed groups, respec-
tively (Figure 5).
Conclusion
The evidence from this review indicates that induction of
labour does not impact the likelihood of delivery by Cae-
sarean section. Two trials, however, showed a significant
reduction in the risk of Caesarean section from a policy of
routine induction of labour among low-risk women with
post-term pregnancy [72,73], though performance bias
may have skewed the results in the Hannah trial.BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2393/9/S1/S6
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Table 4: Impact of elective induction of labour versus expectant management on stillbirths and perinatal mortality
Source Location and Type of Study Intervention Stillbirths/Perinatal Outcomes
Reviews and meta-analyses
Dare et al. 2006 [67] Canada, Scotland, Netherlands, 
Israel, other countries.
Meta-analysis (Cochrane). 5 RCTs 
included (N = 5870 participants).
To assess the effects of planned early 
birth (intervention) vs. expectant 
management (controls) for women 
with term pre-labour rupture of 
membranes on fetal, infant and 
maternal wellbeing.
Fetal death (miscarriage + SB)/PMR: 
OR = 0.46 (95% CI: 0.13–1.66) 
[NS].
[3/2946 vs. 7/2924 in intervention 
and control groups, respectively].
Dodd et al. 2003 [70] Japan (Tokyo).
Cochrane review. 1 RCT included 
(N = 72 participants).
To assess a policy of elective delivery 
from 37 weeks' gestation 
(intervention) vs. an expectant 
approach (controls) for women with 
an otherwise uncomplicated twin 
pregnancy.
PMR: RR not estimable.
[0/34 vs. 0/38 in intervention and 
control groups, respectively].
Gülmezoglu et al. 2006 [64] Thailand, USA, Turkey, Norway, 
Canada, UK, India, Finland, China.
Meta-analysis (Cochrane). 12 
RCTs included (N = 5939 
women).
To assess the impact of a policy of 
labour induction at term or post-
term (intervention) vs. awaiting 
spontaneous labour or later 
induction of labour (controls).
SBR: RR = 0.28 (95% CI: 0.05–1.67) 
[NS].
[0/2986 vs. 4/2953 in intervention 
and control groups, respectively].
PMR: RR = 0.30 (95% CI: 0.09–
0.99).
[1/2986 vs. 9/2953 in intervention 
and control groups, respectively].
Irion et al. 1998 [63] USA, unknown.
Meta-analysis (Cochrane). 2 RCTs 
included (N = 99 women).
To assess the effects of a policy of 
labour induction (intervention) vs. 
expectant management (controls) for 
suspected fetal macrosomia on 
method of delivery and maternal or 
perinatal morbidity.
PMR: RR not estimable.
[0/49 vs. 0/50 in intervention and 
control groups, respectively].
Boulvain et al. 2001 [65] USA.
Cochrane review. 1 RCT included 
(N = 200 women).
To assess the effect of a policy of 
elective delivery (intervention) vs. 
expectant management (controls) in 
term diabetic pregnant women, on 
maternal and perinatal mortality and 
morbidity.
PMR: RR not estimable.
[0/100 vs. 0/100 in intervention and 
control groups, respectively].
Intervention studies
Chattopadhyay et al. 1986 [71] Saudi Arabia.
Prospective, controlled study. 
Grand multiparae (N = 300) 
between 38 and 42 weeks' 
gestation (N = 150 intervention 
group, N = 150 controls).
To compare the impact on labour 
characteristics and outcome in 
women where labour was electively 
induced by intracervical 
prostaglandin E2 tablets 
(intervention) vs. women who went 
into labour spontaneously.
SBR: 0/150 vs. 4/150 in intervention 
and control groups, respectively.
Mean duration of the active phase 
of labour: 2.1 +/- 0.79 h vs. 2.8 +/- 
0.47 h vs. 4.7 +/- 2.2 h in women 
who delivered on the first day of 
induction vs. on the second day vs. 
the controls.
Similarly, the mean duration of the 
second and third stage was longer 
in the controls.
da Graca Krupa et al. 2005 [69] Brazil (Campinas City). Public 
university hospital.
RCT. N = 150 pregnancies, half of 
them allocated to each group.
To compare the effectiveness of 
immediate induction of labour with 
vaginal misoprostol (intervention) vs. 
expectant management for 24 hours 
followed by oxytocin induction 
(controls) in women with premature 
rupture of membranes at term (term 
PROM).
PMR: 0/75 in each group.BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2393/9/S1/S6
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Induction of labour for suspected fetal macrosomia in
non-diabetic women has not been shown to alter the risk
of maternal or neonatal morbidity, but the power of the
included studies to show a difference in rare events is lim-
ited. Large trials are ongoing to address this question.
Induction of labour appears to be an appropriate inter-
vention in post-term pregnancy at 41 completed weeks of
gestation or later. The Cochrane review by Gülmezoglu et
al. [64] comparing elective induction of labour with
expectant management showed a statistically significant
reduction in perinatal mortality and meconium aspira-
tion syndrome. Although increasingly more common-
place, elective inductions are not advised before 39 weeks
gestation given the potential, albeit low, for complica-
tions associated with prematurity. Even in cases of post-
term pregnancy, 500 inductions may be required to pre-
vent one perinatal death. The reduction in stillbirth inci-
dence noted in the Gülmezoglu review was not
statistically significant, likely because the number of still-
births was too small.
Larger RCTs are needed to address the impact of induction
of labour on stillbirth and perinatal mortality for the fol-
lowing indications: suspected macrosomia in non-dia-
betic mothers, multiple pregnancy, and mild pre-
eclampsia.
Drugs for cervical ripening and induction of labour
Background
There are a variety of drugs, including oxytocin and a
number of prostaglandins and prostaglandin analogues,
and many different administration methods including
intracervical, vaginal, oral, and intravenous (IV) routes,
for the induction of labour. Drugs to induce labour can
have adverse side effects, fail to induce labour, or cause
dysfunctional labour or hyperstimulation of the uterus
leading to fetal distress and Caesarean section. Fetal and
possibly maternal death is possible if Caesarean section is
not available or delayed when these drugs are used. The
state of cervical ripening and favourability for induction
should be assessed before a regimen is selected, as oxy-
tocin induction, in particular, often fails unless the cervix
is ripe. In women with unfavourable cervical ripening, dif-
ferent prostaglandin drugs, including prostaglandin F2-
alpha, prostaglandin E2 (dinoprostone), and prostaglan-
din E1 (misoprostol) promote cervical ripening and initi-
ation of labour [74]. Misoprostol is the only
prostaglandin analogue that is effective in inducing
labour without gastrointestinal side effects when given as
Results of new meta-analysis of impact of planned versus expectant management for pre-labour rupture of membranes at term  (by use of prostaglandin) on fetal/perinatal mortality Figure 5
Results of new meta-analysis of impact of planned versus expectant management for pre-labour rupture of 
membranes at term (by use of prostaglandin) on fetal/perinatal mortality.
Study or Subgroup
da Graca Krupa 2005
Hannah 1996
Mahmood 1995
Total (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Events
0
1
0
1
Total
75
1259
50
1384
Events
0
2
0
2
Total
75
1261
50
1386
Weight
100.0%
100.0%
Peto, Fixed, 95% CI
Not estimable
0.50 [0.05, 5.53]
Not estimable
0.50 [0.05, 5.53]
Planned Expectant Odds Ratio Odds Ratio
Peto, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Observational studies
Duff et al. 2000 [150] Ireland. Northern Ireland 
Maternity System (NIMATS).
Retrospective comparative study. 
N = 3262 women who delivered 
during 1994 – 96 (N = 1008 
intervention group, N = 2254 
controls).
Compared the impact on Caesarean 
section rates and Apgar scores in 
women who had labour induced 
(intervention) vs. those in whom the 
labour commenced spontaneously 
(controls).
Caesarean section rate: 12.2% vs. 
7.06% in intervention and control 
groups, respectively [NS] (Chi sq 
= 4.39, p <= 0.2).
1 minute Apgar score: 7.78 vs. 7.9 
in intervention and control groups, 
respectively, t = 2.9, P <= 0.01.
5 minute Apgar score: 8.99 vs. 9.05 
in intervention and control groups, 
respectively, t = 2.42, P <= 0.02).
Table 4: Impact of elective induction of labour versus expectant management on stillbirths and perinatal mortality (Continued)BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2393/9/S1/S6
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an oral preparation. It is inexpensive and stable at room
temperature, making it an easily administered interven-
tion appealing for use in low-resource settings, though the
risk of uterine hyperstimulation at high doses may pro-
duce increased risk of maternal or perinatal death [75].
Insertion of a Foley catheter has also been shown to be as
effective as prostaglandin E2 for stimulating preinduction
cervical ripening, potentially providing an effective, safe,
non-pharmacological mechanical method of preinduc-
tion cervical ripening [76-78].
Given the use of induction for certain indications includ-
ing post-term pregnancy, pre-eclampsia, and PROM in
which the fetus is at higher risk of perinatal death, as well
as the potential for drugs used to induce labour to cause
fetal distress, an assessment of the evidence of impact of
specific drugs available for induction of labour on perina-
tal outcomes is warranted.
Literature-based evidence
Our literature search identified 8 Cochrane reviews and
11 other studies (Table 5) assessing the impact of different
drugs for cervical ripening and/or induction of labour.
The trials identified are grouped below by the drugs being
compared and the route of administration.
Oral misoprostol versus placebo, other prostaglandins, or vaginal 
misoprostol
Alfirevic et al. [75] (Additional file 8) conducted a
Cochrane systematic review of all trials (41 trials, N =
8606 women) comparing oral misoprostol with various
other drugs for induction of labour. No studies comparing
oral misoprostol to placebo reported perinatal outcomes.
Comparing oral misoprostol with vaginal prostaglandin
E2, there was no significant reduction in risk of perinatal
mortality (5 trials, N = 2249, RR = 0.60, 95% CI: 0.08–
4.50); risk of Caesarean section (9 trials, N = 2627 partic-
ipants) reached statistical significance only in the sub-
group with intact membranes (RR = 0.78, 95% CI: 0.66–
0.94). Uterine hyperstimulation was more common after
oral misoprostol (RR = 1.63, 95% CI: 1.09–2.44)
although this was not associated with any adverse fetal
events. Comparing oral misoprostol versus vaginal miso-
prostol preparations, the meta-analysis found no differ-
ence in perinatal outcomes (16 trials, N = 3645
participants) [LOE: 1++].
Vaginal misoprostol versus placebo, other prostaglandins, or oxytocin
A Cochrane review by Hofmeyr et al. [79] (Additional file
9) evaluated 70 RCTs to determine the impact of vaginal
misoprostol for cervical ripening or induction of labour.
Compared to placebo, vaginal misoprostol was associated
with increased success in achieving vaginal delivery within
24 hours (RR = 0.36, 95% CI: 0.19–0.68), but the risk of
uterine hyperstimulation without fetal heart rate changes
was increased (RR = 11.66, 95% CI: 2.78–49). Only one
study reported perinatal mortality and uterine rupture as
outcomes, risk ratios were not determined. The findings
were similar when vaginal misoprostol was compared
with vaginal prostaglandin E2, intracervical prostaglandin
E2, and oxytocin, though none of these interventions had
any differential impact on perinatal outcome. Many stud-
ies were small and reported no perinatal deaths in either
group. Compared with vaginal or intracervical prostaglan-
din E2, oxytocin augmentation was less common and
meconium-stained liquor more common with misopros-
tol [LOE: 1+].
Our literature search identified additional RCTs and a
cohort study not included in the above-mentioned
Cochrane review comparing vaginal misoprostol with
vaginal prostaglandin E2; all indicated no significant dif-
ferences in neonatal outcomes, and none specifically
reported stillbirth rates. RCTs by Garry et al [80][LOE: 1-
] and Lokugamage et al. [81][LOE: 1-] compared vaginal
misoprostol versus vaginal prostaglandin E2 inserts for
cervical ripening and labour induction, finding no signif-
icant differences in perinatal outcomes. A similar RCT by
van Gemund et al  [82] comparing vaginal misoprostol
with prostaglandin E2 for induction of labour found sim-
ilar rates of adverse neonatal outcome in both groups:
21% in the misoprostol and 23% in the prostaglandin E2
groups [LOE: 1+]. An RCT by Rowlands et al. [83] com-
paring vaginal misoprostol and vaginal prostaglandin E2
for cervical priming prior to the induction of labour found
no differences between the groups in low cord pH, Apgar
score at delivery, or admission to the neonatal special care
nursery [LOE: 1-]. An RCT in Greece by Papanikolaou et
al. [84] reported no statistically significant difference in
perinatal mortality in babies born to women receiving
vaginal misoprostol versus vaginal prostaglandin E2 (0/
80 vs. 1/83 [1.2%], respectively) [LOE 1-].
Several other trials compared vaginal misoprostol to oxy-
tocin and other prostaglandins administered via different
administration routes. None reported any significant dif-
ferences in impact on perinatal outcomes. An RCT in
Sudan by Elhassan et al. [85] compared vaginal misopros-
tol to IV oxytocin and reported no difference in birth
weight, Apgar score at birth, or stillbirth rates [LOE: 1-].
Meyer et al [86] found no difference in impact of a single
outpatient dose of vaginal misoprostol (versus intracervi-
cal prostaglandin E2 gel) on subsequent use of oxytocin
for induction, short-term neonatal outcome or rates of
Caesarean delivery [LOE: 1+]. A quasi-RCT in India [87]
comparing vaginal misoprostol to Foley catheter for cervi-
cal dilatation plus IV oxytocin for induction of uterine
contractions reported one stillbirth in the misoprostol
group and none in the oxytocin plus Foley catheter group,
but the sample size was too small to reach statistical sig-BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2393/9/S1/S6
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Table 5: Impact of drugs for cervical ripening and induction of labour on stillbirth and perinatal outcomes
Source Location and Type of Study Intervention Stillbirths/Perinatal 
Outcomes
Reviews and meta-analyses
Kelly et al. 2003 [90] UK, Austria, New Zealand, 
Singapore, USA, Pakistan, Canada.
Meta-analysis (Cochrane). 8 RCTs 
included (N = 3648 women).
To compare the effects of vaginal 
prostaglandins E2 (all regimens) for third 
trimester cervical ripening or induction 
of labour (intervention) vs. placebo/no 
treatment (controls).
PMR: RR = 0.56 (95% CI: 0.14–
2.22) [NS].
[2/1833 vs. 4/1815 in the 
intervention and control groups, 
respectively].
Boulvain et al. 2008 [62] USA, Europe, Africa, UK, Italy.
Meta-analysis (Cochrane). 4 RCTs 
included (N = 1081 women).
Compared the impact on perinatal 
mortality of intracervical prostaglandin 
(prostaglandin E2) (intervention) vs. 
placebo/no treatment (controls) for third 
trimester cervical ripening and induction 
of labour.
PMR: RR = 0.20 (95% CI: 0.01–
4.05) [NS].
[0/587 vs. 2/494 in intervention 
and control groups, respectively].
Hutton et al. 2001 [92] 2 RCTs. Zimbabwe, Australia.
Cochrane review. 2 RCTs 
included (N = 25 women).
To assess the effects of extra-amniotic 
prostaglandin (PGF2 alpha) (intervention) 
for third trimester cervical ripening or 
induction of labour vs. extra amniotic 
placebo gel (controls).
PMR: RR = 2.06 (95% CI: 0.09–
46.11) [NS].
[1/15 vs. 0/10 in intervention and 
control groups, respectively].
Hofmeyr et al. 2003 [79] Chile, Zimbabwe, USA, Canada, 
Jamaica, Malaysia.
Meta-analysis (Cochrane). 7 RCTs 
included (N = 268 women).
To assess the effects of vaginal 
misoprostol for third trimester cervical 
ripening or induction of labour 
(intervention) vs. vaginal prostaglandin 
(controls).
PMR: RR = 2.85 (95% CI: 0.12–
68.95) [NS].
[1/136 vs. 0/132 in intervention 
and control groups, respectively].
Neilson 2000 [94] France, Sweden.
Meta-analysis (Cochrane). 2 RCTs 
included (N = 68 women).
To assess the effects of mifepristone (all 
doses) for third trimester cervical 
ripening or induction of labour 
(intervention) vs. placebo/no treatment 
(controls).
PMR: RR not estimable.
[0/40 vs. 0/28 in intervention and 
control groups, respectively].
French 2001 [89] India, Denmark.
Cochrane review. 2 RCTs 
included (N = 35 women).
To assess the effects of oral prostaglandin 
E2 for third trimester induction of labour 
(intervention) vs. intravenous oxytocin 
(controls) on perinatal mortality.
PMR: RR not estimable.
[0/15 vs. 0/20 in intervention and 
control groups, respectively].
Luckas et al. 2000 [93] USA, UK, Denmark, Belgium and 
Netherlands.
Meta-analysis (Cochrane). 11 
RCTs included (N = 990 women).
To assess the effects of intravenous 
prostaglandin for third trimester cervical 
ripening or induction of labour 
(intervention) vs. IV oxytocin (controls).
PMR: RR = 3.59 (95% CI: 0.60–
21.53) [NS].
[4/499 vs. 0/491 in intervention 
and control groups, respectively].
Alfirevic 2006 [75] Hong Kong, Switzerland, South 
Africa, UK, Spain, Canada, USA.
Meta-analysis (Cochrane). 17 
RCTs included (N = 1508 
women).
To assess the effectiveness and safety of 
oral misoprostol used for labour 
induction in women with a viable fetus in 
the third trimester of pregnancy 
(intervention) vs. vaginal prostaglandin 
(controls).
PMR: RR = 0.60 (95% CI: 0.08–
4.50) [NS].
[data from 4 RCTs; 1/756 vs. 2/
752 in intervention and control 
groups, respectively].
Intervention studies
Elhassan et al. 2005 [85] Sudan.
Non-blinded RCT. N = 140 
patients (N = 70 intervention, N = 
70 controls).
Assessed the impact of vaginal 
misoprostol, 50 μg, six hourly until 
initiation of labour or maximum of 4 
doses (intervention) vs. IV infusion of 
oxytocin at 2 mU/min, doubled at 30-
minute intervals until the appropriate 
contraction pattern obtained or dose 
increased to a maximum of 20 mU/
minute and maintained as such (controls).
Neonatal outcomes (birth weight, 
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Garry et al. 2003 [80] USA.
RCT. Singleton gestations (N = 
200) with an indication for cervical 
ripening and induction of labour.
Compared the impact of 50 μg of vaginal 
misoprostol every 3 h (intervention) vs. a 
10-mg prostaglandin E2 vaginal insert 
every 12 h for a maximum of 24 h 
(controls).
Neonatal outcomes: [NS]
Vaginal delivery <12 hr: 44% vs. 
12% in misoprostol vs. 
prostaglandin E2 group, 
respectively (P < 0.0001)
Vaginal delivery <24 hr: 68% vs. 38 
in misoprostol vs. prostaglandin 
E2 group, respectively (P < 0.001).
Caesarean delivery for fetal 
distress: 71.4% (20/28) vs. 40% 
(14/35) in misoprostol group vs. 
prostaglandin E2 group (P = 0.03).
Jindal et al. 2007. [87] India.
Quasi-RCT. N = 100 women (N = 
50 intervention group, N = 50 
controls).
Compared the impact of 50 μg of vaginal 
misoprostol 4 hourly for a maximum of 
six doses (intervention) vs. transcervical 
Foley catheter with simultaneous 
intravenous oxytocin (controls).
SBR: 1/50 vs. 0/50 in intervention 
and control groups, respectively.
Lokugamage et al. 2003 [81] UK. Hospital based.
RCT. N = 191 patients.
Compared the impact of 50 μg vaginal 
misoprostol initially then a further 
identical dose 6 hrs later (intervention) 
vs. 2 mg vaginal prostaglandin E2 initially 
followed by 1 mg 6 hrs later, over a 
period of 24 hrs (controls). All 
participants not in labour after 24 hrs 
received prostaglandin E2 alone as per 
hospital protocol.
Neonatal outcome: [NS]
Induction-to-delivery interval: 
1047 vs. 1355 min (P = 0.01) in 
intervention and control groups, 
respectively.
Delivery <12 hrs: 35.4% vs. 18.9%, 
(P = 0.02) in intervention and 
control groups, respectively.
Delivery <24 hrs: 83.3% vs. 63.3%, 
(P = 0.01) in intervention and 
control groups, respectively.
Oxytocin augmentation: [NS] (P 
= 0.47),
Tachysystole: [NS] (P = 0.32) and
Hyperstimulation syndrome: 
[NS] (P = 0.82).
Majoko et al. 2002 [151] Zimbabwe.
RCT. N = 152 women admitted 
for induction of labour (N = 76 in 
each group).
Compared the impact of vaginal 
misoprostol (intervention) versus extra-
amniotic prostaglandin F2α gel (controls).
SBR: 1/76 in each group due to 
asphyxia (both mothers induced 
for pre-eclampsia; deaths resulting 
from inadequate response to fetal 
distress).
Meyer et al. 2005 [86] USA.
RCT. N = 84 patients.
Compared the impact of 0.25μg 
misoprostol vaginally (intervention) vs. 
0.5 mg prostaglandin E2 gel intracervically 
(controls), the evening before oxytocin 
induction.
Neonatal outcome: [NS]
Caesarean rate: 9/42 vs. 8/42 in 
intervention and control groups, 
respectively [NS]
Papanikolaou et al. 2004 [84] Greece.
RCT. Nulliparous pregnant 
women (N = 163) with an 
unfavorable cervix and > 285 days 
of gestation (N = 80 intervention 
group, N = 83 controls).
Compared the efficacy of 50 μg vaginal 
misoprostol (intervention) versus 3 mg 
prostaglandin E2 (controls), administered 
every 9 hrs for a maximum of three 
doses for elective induction of labour.
SBR or PMR: 0/80 vs. 1/83 (1.2%) 
in intervention and control 
groups, respectively [NS].
Rowlands et al. 2001 [83] Australia.
RCT. N = 126 women recruited 
to the study (N = 63 in each 
group).
Compared the effect on neonatal 
outcomes of vaginal prostaglandin E2 
(group 1) vs. vaginal misoprostol 
(controls) for cervical priming prior to 
induction of labour.
Neonatal outcome (low cord pH, 
Apgar score at delivery or 
admission to the neonatal special 
care nursery): [NS]
Table 5: Impact of drugs for cervical ripening and induction of labour on stillbirth and perinatal outcomes (Continued)BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2393/9/S1/S6
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Sahin et al. 2002 [88] Turkey.
RCT. N = 100 pre-eclamptic 
women with a modified Bishop 
score of = 4 (N = 50 in each 
group).
Compared the impact of 50 μg vaginal 
misoprostol 4 times at 4 hour intervals 
(intervention) vs. oxytocin infusion for 
induction of labour starting from 1 mIU/
per min, increasing it every 30 min with 2 
mIU/min increments up to maximum of 
30 mIU/min (controls).
Intrapartum SB: 0/50 in both 
groups.
Sahraoui et al. 2005 [91] Tunisia.
RCT. All uncomplicated 
pregnancies that reached 41 
weeks'gestation with a Bishop 
score of < or = 4.
Compared the impact on fetal outcomes 
of cervical prostaglandin E2 gel for 
cervical ripening (intervention) vs. 
control.
Caesarean rates: [NS]
Rates of admission into the 
neonatal unit and fetal outcomes: 
[NS]
Van Gemud et al. 2004 [82] The Netherlands. Labour wards of 
one university hospital and two 
teaching hospitals.
RCT. Women (N = 681) with 
indication for labour induction at > 
or = 36 weeks of gestation, 
singleton pregnancy and no 
previous Caesarean section.
Compared the impact on pregnancy 
outcomes of misoprostol (25 mcg, 
hospital-prepared capsule) in the 
posterior vaginal fornix, every four hours, 
maximum three times daily (intervention) 
vs. prostaglandin E2 gel every four hours 
(controls). Oxytocin was administered if 
necessary
Neonatal deaths: (excluding 
malformations): 0 in both groups.
Adverse neonatal outcome: 21% 
vs. 23% in intervention and 
control groups, respectively 
[NS].
Median induction-delivery interval: 
25 vs. 19 h in intervention and 
control groups, respectively (P = 
0.008).
Caesarean rate: RR = 0.8 (95% CI: 
0.6–1.04) [NS].
[16.1% vs. 21% in intervention and 
control groups, respectively].
Admission to NICU: RR = 0.7 
(95% CI: 0.5–0.98).
[19% vs. 26% in intervention and 
control groups, respectively].
Table 5: Impact of drugs for cervical ripening and induction of labour on stillbirth and perinatal outcomes (Continued)
nificance [LOE: 2+]. A similar RCT of vaginal misoprostol
versus IV oxytocin in Turkey by Sahin et al. [88] reported
no intrapartum stillbirths in either group (0/50 in each
group) [LOE: 1+].
Oral prostaglandins versus IV oxytocin
One Cochrane review by French et al. [89] (Additional file
10) compared oral prostaglandin E2 for third trimester
induction of labour to IV oxytocin (2 RCTs, N = 35
women), reporting no perinatal deaths in either group (0/
15 vs. 0/20 in prostaglandin E2 versus IV oxytocin groups,
respectively).
Intracervical prostaglandins versus placebo
A Cochrane review by Boulvain et al. [62] (28 trials, N =
3764 women) comparing intracervical prostaglandins
with placebo found a trend toward a lower PMR in the
prostaglandin group but the result was not significant (RR
[fixed] = 0.20, 95% CI: 0.01–4.05 [NS]) (Additional file
11). Prostaglandin E2 was associated with a decreased rate
of labours lasting more than 24 hours versus placebo (4
trials, RR = 0.61, 95% CI: 0.47–0.79), but only a trend
toward reduced risk of Caesarean section (RR = 0.88, 95%
CI: 0.77–1.00). This decreased Caesarean section risk was
statistically significant in the subgroup of women with
intact membranes and unfavourable cervix (RR = 0.82;
95% CI: 0.68–0.98). The risk of hyperstimulation with
fetal heart rate changes was not significantly increased (RR
= 1.21; 95% CI: 0.72–2.05). However, the risk of hyper-
stimulation without fetal heart rate changes was signifi-
cantly increased (RR = 1.59, 95% CI: 1.09–2.33) [LOE:
1+].
Vaginal prostaglandins versus placebo
Kelly et al. [90] conducted a Cochrane review to deter-
mine the effects of vaginal prostaglandins E2 and F2α for
cervical ripening or induction of labour in comparison
with placebo/no treatment, and reported a non-signifi-
cant reduction in PMR (RR [fixed] = 0.56, 95% CI: 0.14–
2.22 [NS])[LOE: 1+] (Additional file 12). One RCT com-
pared vaginal prostaglandin E2 versus placebo [91],
reporting no difference in fetal or neonatal outcomes or
rates of Caesarean section [LOE: 2-].
Extra-amniotic prostaglandins versus placebo
A Cochrane review by Hutton et al. [92] compared the
impact of extra-amniotic PGF2 versus extra-amniotic pla-
cebo gel for third trimester cervical ripening or induction
of labour, and found no significant impact on PMR (RR
[fixed] = 2.06, 95% CI: 0.09–46.11 [NS])[LOE: 1++]
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Intravenous prostaglandins versus intravenous oxytocin
A Cochrane review by Luckas et al. [93] determined the
effects of IV prostaglandin versus IV oxytocin for third tri-
mester cervical ripening or induction of labour, and
reported a non-significant trend toward increased risk of
perinatal mortality with IV prostaglandin (RR [fixed] =
3.59, 95% CI: 0.60–21.53 [NS]) [LOE: 1+] (Additional
file 14).
Mifepristone versus placebo
A Cochrane analysis by Neilson [94] assessed the effec-
tiveness of mifepristone, typically used to induce abortion
or induce labour in cases of antepartum miscarriage or
stillbirth, versus placebo in cervical softening and induc-
tion of labour (2 trials, N = 68 women). There were no
perinatal deaths in either group (Additional file 15).
New meta-analysis
Vaginal misoprostol versus prostaglandin E2
We included 4 RCTs reporting perinatal death as outcome
in a meta-analysis comparing vaginal misoprostol to pros-
taglandin E2 for inducing labour (N = 431 women; N =
216 misoprostol, N = 215 prostaglandin E2). We found
no difference in perinatal death comparing misoprostol to
prostaglandin E2 (RR [fixed] = 0.99, 95% CI: 0.14–7.13;
RR [random] = 0.99, 95% CI: 0.10–9.45) (Figures 6 and
7).
Conclusion
Both vaginal and oral misoprostol are more effective than
placebo and comparable to intravenous oxytocin or vagi-
nal prostaglandin E2 in inducing labour at term [75,79].
Misoprostol at any dosage carries higher risk of meco-
nium staining, but this was not associated with any
adverse perinatal outcomes. Compared with vaginal pros-
taglandins, oral misprostol appears to reduce rates of Cae-
sarean section [79] and vaginal misoprostol is associated
with shorter labour, fewer side effects, and lower inci-
dence of retained placenta, with no difference in perinatal
mortality. However, there remain questions about the
safety of both vaginal and oral misoprostol because of a
relatively high rate of uterine hyperstimulation and the
Results of new meta-analysis (Random model) of impact of vaginal misoprostol vs. prostaglandin E2 for cervical ripening and  induction of labour on perinatal mortality Figure 7
Results of new meta-analysis (Random model) of impact of vaginal misoprostol vs. prostaglandin E2 for cervi-
cal ripening and induction of labour on perinatal mortality.
Study or Subgroup
Fletcher 1994
Kolderup 1999
Lee 1997
Papanikolaou 2004
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.84, df = 1 (P = 0.36); I² = 0%
Test for overall effect: Z = 0.01 (P = 1.00)
Events
0
1
0
0
1
Total
31
80
25
80
216
Events
0
0
0
1
1
Total
31
76
25
83
215
Weight
50.0%
50.0%
100.0%
M-H, Random, 95% CI
Not estimable
2.85 [0.12, 68.95]
Not estimable
0.35 [0.01, 8.36]
0.99 [0.10, 9.45]
Vaginal Misoprostol Vaginal Prostaglandin Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Results of new meta-analysis (Fixed model) of impact of vaginal misoprostol vs. dinoprostone for cervical ripening and induc- tion of labour on perinatal mortality Figure 6
Results of new meta-analysis (Fixed model) of impact of vaginal misoprostol vs. prostaglandin E2 for cervical 
ripening and induction of labour on perinatal mortality.
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lack of appropriate dose ranging studies. While no
increase in adverse fetal outcomes was reported in any of
the misoprostol studies, the number of adverse fetal out-
comes was too few to draw meaningful conclusions. There
is no evidence to support the selective use of either oral or
vaginal misoprostol on either perinatal mortality or still-
births.
There was no statistically significant impact of any pros-
taglandin preparation on perinatal outcomes; it should be
noted that most studies reviewed were small and the num-
bers of adverse outcomes too small to accurately measure
differences in stillbirth or perinatal mortality rates
between study arms. Vaginal prostaglandin E2, especially
as vaginal tablets, appears to be an effective labour induc-
tion agent, improving the likelihood of vaginal delivery
within 24 hours and reducing the need for augmentation
with oxytocin, without increasing the risk of Caesarean
section [90]. Vaginal prostaglandin E2 may reduce perina-
tal mortality, but the non-significant findings in the
Cochrane review by Kelly et al indicate the need for fur-
ther large RCTs. The intracervical mode of administration
of prostaglandins is less used and less well evaluated than
other modes of administration [62], and appears to be
less effective in inducing labour than vaginal prostaglan-
din application, with no benefit for perinatal mortality.
The data for perinatal mortality associated with extra-
amniotic prostaglandins are extremely limited and
require further trials [92].
Planned Caesarean section for breech presentation
Background
Approximately 3–4% of term singleton pregnancies are
complicated by breech presentation at term, and in most
high-income countries, the majority of these births are
handled via either planned or emergency Caesarean sec-
tion. Whether planned caesarean section for breech pres-
entation at term results in better perinatal outcomes is a
contentious issue. An alternative to breech Caesarean sec-
tion or breech vaginal delivery is external cephalic version,
which has been shown to reduce numbers of breech births
and breech Caesarean sections without impacting perina-
tal mortality [95,96]. Until recently the major evidence for
Caesarean section for breech presentation has been
derived from patient case studies and register studies lack-
ing sufficient rigor on which to make policy or clinical
management recommendations. Here, we review the evi-
dence for impact of planned Caesarean section for breech
presentation on perinatal mortality and stillbirth rates.
Literature-based evidence
Our literature search identified 1 Cochrane review and 3
other intervention/observational studies assessing the
impact of planned Caesarean section for breech presenta-
tion on perinatal mortality outcomes (Table 6). The
Cochrane review by Hofmeyr et al. [97] (Additional file
16) evaluated RCTs (3 trials, N = 2396 women), including
the large Term Breech Trial [98], comparing planned Cae-
sarean section with planned vaginal birth for singleton
breech presentation at term. Perinatal or neonatal death
(excluding fatal anomalies) or serious neonatal morbidity
was reduced with planned Caesarean section compared to
planned vaginal delivery [3/1166 (0.26%) vs. 14/1222
(1.15%), respectively; RR = 0.29, 95% CI: 0.10–0.86; 3 tri-
als; N = 2388 women]. Compared with planned vaginal
breech delivery, planned Caesarean section was associated
with an increased risk of avoidable short-term maternal
morbidity, including postpartum infection, haemorrhage,
and anaemia (RR = 1.29, 95% CI: 1.03–1.61) [LOE: 1+].
In Switzerland, a cohort study by Irion et al. [99] of
planned vaginal versus planned Caesarean section for
breech singleton presentation at term (N = 705 women)
found a non-significant increased risk of neonatal mortal-
ity among the group delivering vaginally, but all deaths
were attributable to major malformations (1% vs. 0.3% in
planned vaginal vs. Caesarean section groups, RR = 3.33,
95% CI: 0.37–29.60 [NS]) [LOE: 2-].
In The Netherlands, Molkenboer et al. [100] conducted a
2-centre retrospective matched cohort study including all
singleton breech deliveries from 1998–2000 of at least 37
and less than 42 weeks' gestation, excluding antepartum
stillbirths, but no perinatal deaths occurred in either
group [LOE: 2-].
Conclusion
The above evidence for planned caesarean section delivery
for singleton breech presentation at term indicates that
this intervention is associated with a statistically signifi-
cant reduction in perinatal and neonatal mortality and
morbidity, though it is associated with increased short-
term maternal morbidity associated with recovery from a
Caesarean section. The largest study in the Cochrane
review, the Term Breech Trial, demonstrates strong evi-
dence of benefit of planned caesarean section in reducing
perinatal mortality, though it should be noted that no
point estimates for impact on stillbirths were reported.
Additionally, a number of methodological and analytical
criticisms have been levied at the largest study in the
Cochrane review (the Term Breech Trial, whose principal
investigator co-authored the Cochrane review) including
a lack of adherence to inclusion criteria, great variability in
level of care between facilities and labours (including
insufficient monitoring in some cases), and a lack of clini-
cians with expertise in vaginal breech delivery, Glezerman
M: Five years to the term breech trial: the rise and fall of a
randomised controlled trial. Am J Obstet Gynecol 2006,
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Although planned Caesarean for breech presentation
appears to be a promising intervention, in light of these
criticisms and the downstream implications of recom-
mending a policy of Caesarean section in low-resource
settings, our recommendation for Caesarean section in
term breech presentation carries several caveats. Given the
risks associated with Caesarean section, a planned Caesar-
ean section should only be considered after external
cephalic version has been unsuccessful and sufficient time
has been allowed for spontaneous version and cephalic
birth to take place [95]. Caesarean section poses short-
term risks of infection and haemorrhage, as well as long-
term risks including uterine rupture (particularly where a
classical incision is performed), placental invasion of the
uterine scar, stillbirth, and maternal death, for women
who cannot or do not access facilities with comprehensive
essential obstetric care in subsequent pregnancies. For
these reasons, in some low-resource settings, the compli-
cations associated with Caesarean section may pose
greater risks to both mothers' and babies' lives than vagi-
nal delivery for breech presentation. Vaginal birth for
breech presentations is advised in these circumstances, as
97% of breech-position singleton infants will be born
without complications [97]. Additionally, adoption of a
policy of breech delivery by Caesarean section will ulti-
mately lead to the disappearance of the specialised clinical
skills required to perform vaginal breech delivery, mean-
ing that women with breech fetuses who do deliver vagi-
nally may face greater risk.
Magnesium sulphate supplementation for pre-eclampsia/
eclampsia and pre-term labour
Background
Magnesium sulphate has both anti-convulsant and toco-
lytic applications. Anti-convulsants, including magne-
sium sulphate, diazepam, and phenytoin, are a key
strategy for preventing or stopping eclamptic seizures in
pregnant women with pre-eclampsia and eclampsia,
respectively, which account for 50,000 maternal deaths
per year worldwide (10% of all direct maternal deaths)
[101]. Magnesium sulphate is generally regarded as the
first choice drug, and superior to diazepam or phenytoin,
Table 6: Impact of planned Caesarean section for breech presentation on stillbirth and perinatal mortality
Source Location and Type of Study Intervention Stillbirths/Perinatal 
Outcomes
Reviews and meta-analyses
Hofmeyr et al. 2003 [97] USA.
Meta-analysis (Cochrane). 3 RCTs 
included (N = 2388 women).
To assess the effects of planned 
Caesarean section for singleton breech 
presentation at term (intervention) vs. 
planned vaginal delivery on measures of 
pregnancy outcome.
PMR/NMR (excluding fatal 
malformations): RR = 0.29 (95% 
CI: 0.10–0.86).
[3/1166 vs. 14/1222 in 
intervention and control groups, 
respectively].
Intervention studies
Irion et al. 1998 [99] Switzerland (Geneva). University 
hospital.
Cohort study. N = 705 consecutive 
singleton term breech presentations (N 
= 385 planned vaginal deliveries, N = 
320 planned Caesarean sections).
Compared the impact on neonatal 
mortality of planned vaginal delivery vs. 
elective Caesarean section in term 
breech presentations.
NMR (all major malformations): 
RR = 3.33 (95% CI: 0.37–29.60).
[1% vs. 0.3% in planned vaginal vs. 
Caesarean groups, respectively; P 
= 0.38].
Molkenboer et al. [100] The Netherlands. 2 centres.
Retrospective matched cohort study. N 
= 1119 deliveries between July 1998 and 
April 2000 (N = 373 breech between 
37(+0) and 41(+6) weeks, N = 746 
cephalic position).
Compared the impact on perinatal 
mortality in babies with breech 
presentation (exposed) vs. those with 
cephalic presentation (unexposed).
PMR: 0 in both groups.
Planned Caesarean: 23.3% vs. 
3.5% in breech vs. cephalic 
deliveries, respectively; P < 0.001.
Emergency Caesarean: 29.2% vs. 
8.8% in exposed vs. unexposed 
groups, respectively; P < 0.001.
Nalliah et al. 2009 [152] Malaysia (Ipoh). Hospital based study.
Retrospective analysis. N = 4886 breech 
presentations from 1992–2004, of which 
3725 were evaluated.
Compared perinatal mortality among 
breech births delivered vaginally versus 
by Caesarean section.
PMR: Mode of delivery did not 
improve PMR in breech cases.BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2393/9/S1/S6
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for controlling eclamptic fits and preventing associated
maternal and fetal deaths [102-104]. However, the use of
magnesium sulphate presents potential hazards including
severe maternal adverse effects such as respiratory and car-
diac arrest, and risk of fetal neurological depression (e.g.,
decreased respiratory effort), suggesting that while mag-
nesium sulphate may prevent some fetal and neonatal
deaths due to eclampsia, it may present an increased risk
of harm in some pregnancies.
Magnesium sulphate also has tocolytic properties: it
relaxes smooth muscle and inhibits uterine contractile
activity. Tocolytic drugs can theoretically prevent or delay
labour and pre-term birth for women at high risk of pre-
term delivery [105]. Ideally, a tocolytic agent would delay
labour long enough to administer corticosteroids to has-
ten fetal lung maturation prior to delivery. Magnesium
sulphate is widely used as a tocolytic agent for preventing
pre-term birth in the United States [106]; below, we
explore the evidence for the impact of its use on stillbirth.
Literature-based evidence
Our literature search identified 4 Cochrane reviews on the
role of magnesium sulphate for management of pre-
eclampsia and eclampsia and 3 Cochrane reviews and 1
other study on its role in threatened preterm labour (Table
7). The role of antenatal magnesium supplementation in
prevention of pre-eclampsia in magnesium-deficient pop-
ulations has been discussed in a previous paper in this
series [107].
Magnesium sulphate for treatment of pre-eclampsia and eclampsia
A Cochrane review by Duley et al. [108] (Additional file
17) compared the impact of magnesium sulphate versus
placebo or no treatment in women with pre-eclampsia,
and reported no difference in the risk of stillbirth and/or
neonatal death (3 trials; RR = 1.04, 95% CI: 0.93–1.15)
[LOE: 1++]. A second Cochrane review by Duley et al.
[103] (Additional file 18) comparing magnesium sul-
phate with diazepam in eclampsia cases showed no differ-
ence in stillbirth rates between the two treatments (RR =
0.89, 95% CI: 0.63–1.26); a separate Cochrane review
[104] comparing magnesium sulphate to phenytoin
found a similar non-significant impact on stillbirth rates
(2 trials, 665 babies, RR = 0.83, 95% CI: 0.61–1.13). How-
ever, magnesium sulphate was associated with fewer
admissions of babies to a neonatal special care unit (1
trial, N = 518 babies, RR = 0.73, 95% CI: 0.58–0.91), and
fewer neonatal deaths or special care unit admissions
exceeding 7 days (1 trial, N = 665 babies, RR = 0.77, 95%
CI: 0.63–0.95) [LOE: 1+] (Additional file 19).
Duley et al. [109] (Additional file 20) evaluated RCTs
comparing any use of magnesium sulphate with any use
of lytic cocktail (a combination of drugs, usually chlo-
rpromazine, promethazine and pethidine) in women
with eclampsia (2 trials, N = 199 women). Magnesium
sulphate proved superior to lytic cocktail in preventing
further seizures (RR = 0.09, 95% CI: 0.03–0.24), but the
comparative impact of magnesium sulphate on stillbirths
was not statistically significant (RR = 0.55, 95% CI-0.26–
1.16) [LOE: 1+].
Magnesium sulphate for prevention of preterm birth
Doyle et al. [110] reviewed RCTs of studies evaluating the
impact of antepartum magnesium sulphate therapy in
women at high risk of, or with threatened, pre-term
labour (4 trials, N = 3701 babies) (Additional file 21).
There was no difference in risk of fetal death between
women administered magnesium sulphate versus no
magnesium sulphate (RR = 0.98, 95% CI: 0.78–1.24, 4 tri-
als). Additionally, there was no impact of antepartum
magnesium sulphate therapy on paediatric mortality (RR
= 0.97, 95% CI: 0.74–1.28, 4 trials, 3701 infants) or neu-
rological impairments or disabilities in early childhood
[LOE: 1++]. A second, large Cochrane review of the use of
magnesium sulphate to prevent preterm birth by
Crowther et al. [105] reported an elevated risk of baby
death (fetal plus infant death) among infants exposed to
magnesium sulphate (RR = 2.82, 95% CI: 1.20–6.62, 7 tri-
als, 727 infants) (Additional file 22). Considering fetal
deaths separately, there was no significant impact on risk
of fetal death (1 trial, RR = 5.70, 95% CI: 0.28–116.87
[NS]); both fetal deaths occurred in just 1 of the 7 studies
reporting fetal or child death. Magnesium sulphate made
no difference in the risk of delivery within 48 hours of
treatment (RR = 0.85, 95% CI: 0.58–1.25, 11 trials, 881
women) compared to controls not given magnesium sul-
phate. Similarly, no benefit was seen for magnesium sul-
phate on the risk of giving birth pre-term (<37 weeks) or
very pre-term (<34 weeks). The third Cochrane review
[111] on magnesium maintenance therapy after adminis-
tration of an initial tocolytic for preventing preterm
births, had 3 trials, including 303 women. The magne-
sium group had a five-fold higher risk of perinatal mortal-
ity than placebo, no or alternative treatment (Additional
file 23).
A multicentre RCT of magnesium sulphate use to reduce
cerebral palsy and death by Rouse et al. [112] in women
at risk of preterm birth between 24 and 31 weeks of gesta-
tion showed that the women in the intervention group
had a statistically non-significant slightly elevated risk of
the composite outcome of stillbirth or infant death (RR =
1.12; 95% CI: 0.85–1.47). Risk of moderate or severe cer-
ebral palsy was significantly lower in children of women 
given magnesium sulphate compared to placebo (RR =
0.55; 95% CI: 0.32–0.95) [LOE 1+].BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2393/9/S1/S6
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Conclusion
Intravenous or intramuscular magnesium sulphate signif-
icantly decreases the risk of eclampsia. IV or intramuscular
magnesium sulphate appears to be substantially more
effective than diazepam and phenytoin for treatment of
eclampsia, and is therefore the treatment of choice. No tri-
als reported any statistically significant impact of magne-
sium sulphate on stillbirth incidence or perinatal
mortality.
Among women deemed to be at risk of preterm birth,
magnesium sulphate is ineffective at delaying or prevent-
Table 7: Impact of magnesium sulphate in treatment of pre-eclampsia/eclampsia and threatened pre-term labour on stillbirth and 
perinatal mortality
Source Location and Type of Study Intervention Stillbirths/Perinatal 
Outcomes
Magnesium sulphate for treatment of pre-eclampsia and eclampsia
Reviews and meta-analyses
Duley 2003 [108] Bangladesh, South Africa, USA, 
Malaysia.
Meta-analysis (Cochrane). 5 RCTs 
included (N = 9,961 women).
To assess the effects of magnesium 
sulphate for pre-eclampsia 
(intervention) vs. placebo or no anti-
convulsant (controls) on the women 
and their children.
SBR: RR = 0.99 (95% CI: 0.87 – 
1.12) [NS].
[424/5003 vs. 426/4958 in 
intervention and control groups, 
respectively].
PMR: RR = 0.98 (95% CI: 0.88 – 
1.10) [NS].
[538/4655 vs. 541/4604 in 
intervention and control groups, 
respectively].
Duley et al. 2000 [109] India.
Meta-analysis (Cochrane). 2 RCTs 
included (N = 177 women).
To compare the effects of 
magnesium sulphate (intervention) 
vs. those of lytic cocktail (controls) 
when used for the care of women 
with eclampsia.
SBR: RR = 0.55 (95% CI: 0.26 – 
1.16) [NS].
[9/89 vs. 16/88 in intervention and 
control groups, respectively].
NMR: RR = 0.39 (95% CI: 0.14 – 
1.06) [NS].
[5/90 vs. 13/93 in intervention and 
control groups, respectively].
Duley et al. 2003 [104] South Africa, India.
Meta-analysis (Cochrane). 2 RCTs 
included (N = 665 women).
To assess the effects of magnesium 
sulphate (intervention) vs. phenytoin 
(controls) when used for the care of 
women with eclampsia.
SBR: RR = 0.83 (95% CI: 0.61 – 
1.13) [NS].
[57/325 vs. 72/340 in intervention 
and control groups, respectively].
PMR: RR = 0.85 (95% CI: 0.67 – 
1.09) [NS].
[84/325 vs. 103/340 in 
intervention and control groups, 
respectively].
NMR: RR = 0.95 (95% CI: 0.59 – 
1.53) [NS].
[29/325 vs. 32/340 in intervention 
and control groups, respectively].
Duley et al. 2003 [103] Malaysia, Zimbabwe, Africa, Asia 
and South America.
Meta-analysis (Cochrane). 4 RCTs 
included (N = 756 women).
To assess the effects of magnesium 
sulphate (intervention) vs. diazepam 
(controls) when used for the care of 
women with eclampsia.
SBR: RR = 0.89 (95% CI: 0.63 – 
1.26) [NS].
[51/385 vs. 55/371 in intervention 
and control groups, respectively].
PMR: RR = 1.04 (95% CI: 0.80 – 
1.36) [NS].
[87/379 vs. 80/366 in intervention 
and control groups, respectively].
NMR: RR = 1.34 (95% CI: 0.84 – 
2.14) [NS].
[38/364 vs. 27/352 in intervention 
and control groups, respectively].BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2393/9/S1/S6
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ing labour, and while its use may be associated with side
effects in the infant such as neurological depression, there
is evidence that magnesium sulphate may also prevent
moderate or severe cerebral palsy in live-born infants
[112]. There is not enough evidence to show any differ-
ence between magnesium maintenance therapy and
either placebo or no treatment, or alternative therapies
(other tocolytics, for example) in preventing preterm birth
after an episode of threatened preterm labour. Thus,
despite good quality evidence and impact on maternal
pre-eclampsia (Grade A), evidence for impact of magne-
sium therapy on stillbirth prevention is insufficient.
Maternal hyperoxygenation for suspected impaired fetal 
growth
Background
Long-term fetal hypoxia, which results from diminished
oxygen and/or nutrient flow to the fetus from the mother,
is often implicated in cases of impaired fetal growth.
Impaired fetal growth may result from a number of fac-
tors, including fetal characteristics (e.g., congenital abnor-
malities), placental factors (e.g., small placenta, poor
placentation), and maternal conditions (e.g., drug use,
malnutrition, renal or vascular problems) [113]. Severe
deprivation of oxygen and/or nutrients can result in
hypoxia or nutrient deprivation so severe as to cause still-
birth. Several observational uncontrolled trials have eval-
uated the physiological basis for maternal
hyperoxygenation (40–55% humidified oxygen by face
mask at 8 litres per minute, 24 hours per day) as a way to
improve oxygen flow to the fetus and thereby alleviate
hypoxia and stimulate nutrient transfer [114-118]
Literature-based evidence
Our literature search identified 1 Cochrane review and 1
other intervention study (Table 8) that evaluated the
impact of maternal hyperoxygenation on perinatal mor-
tality. Say et al. [119] reviewed RCTs (3 RCTs, N = 94
Magnesium sulphate for threatened pre-term labour.
Reviews and meta-analyses
Crowther et al. 2002 [105] USA.
Meta-analyses (Cochrane). 7 RCTs 
included (N = 635 women).
To assess the effectiveness and 
safety of magnesium sulphate 
therapy (intervention) vs. placebo, 
no placebo or alternative tocolytic 
therapy (controls) given to women 
in threatened pre-term labour with 
the aim of preventing pre-term birth 
and its sequelae.
Fetal deaths (miscarriage+SB): RR 
= 5.70 (95% CI: 0.28 – 116.87) 
[NS].
[2/293 vs. 0/342 in intervention 
and control groups, respectively].
Crowther and Moore 1998 [111] USA.
Cochrane review. 1 RCT included 
(N = 50 women).
To assess the effects of magnesium 
maintenance therapy (intervention) 
vs. placebo/no treatment (controls) 
on preventing pre-term birth after 
threatened pre-term labour.
Death before hosp discharge: RR 
= 5.00 (95% CI: 0.25 – 99.16) 
[NS].
[2/25 vs. 0/25 in intervention and 
control groups, respectively].
Doyle et al. 2007 [110] Australia, New Zealand, France, 
USA.
Meta-analysis (Cochrane). 4 RCTs 
included (N = 3,701 women).
To assess the effectiveness and 
safety of magnesium sulphate as a 
neuroprotective agent (intervention) 
vs. placebo or no placebo (controls) 
when given to women considered at 
risk of pre-term birth.
Fetal death (miscarriage + SB): RR 
= 0.98 (95% CI: 0.78 – 1.24) [NS].
[123/1864 vs. 125/1837 in 
intervention and control groups, 
respectively].
Intervention studies
Rouse et al. 2008 [112] USA. Multicentre.
RCT. N = 2241 women 24–31 
weeks of gestation deemed at high 
risk of pre-term labour.
Compared the impact of IV 
magnesium sulphate (a loading dose 
of 6 g infused for 20 to 30 minutes, 
followed by a maintenance infusion 
of 2 g per hour) (intervention) with 
identical-appearing placebo 
(controls).
SBR+IMR): RR = 1.12 (95% CI: 
0.85 – 1.47); P = 0.41 [NS].
[99/1041 (9.5%) vs. 93/1095 (8.5%) 
in intervention and control 
groups, respectively].
Moderate or severe cerebral 
palsy: RR = 0.55 (95% CI: 0.32–
0.95); P = 0.03.
[20/1041 (1.9%) vs. 38/1095 (3.5%) 
in intervention and control 
groups, respectively].
Table 7: Impact of magnesium sulphate in treatment of pre-eclampsia/eclampsia and threatened pre-term labour on stillbirth and 
perinatal mortality (Continued)BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2393/9/S1/S6
Page 29 of 43
(page number not for citation purposes)
women) comparing maternal oxygen therapy with no
oxygen therapy in suspected impaired fetal growth, and
found statistically significantly lower PMR in the oxygen-
ation group compared to the non-oxygen group in all
three included trials (RR = 0.50, 95% CI: 0.32–0.81).
However, the reviewers cautioned that higher gestational
age in the oxygenation groups might have accounted for
the difference in mortality rates [LOE: 1++] (Additional
file 24).
A quasi-RCT by Battaglia et al. [120] attempted to com-
pare the impact of maternal oxygenation versus no oxygen
in a group of pregnant women (N = 38) prescribed bed
rest, but no perinatal deaths occurred in either group
[LOE: 2-].
Conclusion
The evidence for maternal hyperoxygenation in the
Cochrane suggests that in pregnant women treated with
long-term oxygen therapy, perinatal mortality is signifi-
cantly reduced [119]. Methodological deficiencies in the
trials included in the Cochrane review, including the
greater average gestational age of fetuses in the oxygen
intervention groups and the small size of the included tri-
als, suggest that this promising finding must be confirmed
with rigorous, large multicentre RCTs reporting stillbirths
and early neonatal mortality separately. Interestingly,
while there appeared to be an impact on perinatal mortal-
ity, maternal hyperoxygenation did not appear to improve
fetal growth. We classify maternal hyperoxygenation as
having some evidence of benefit in reducing perinatal
mortality given the promising findings of the Cochrane
review on this subject, but suggest that this intervention
not be included in programs until confirmatory results
become available, as some prior studies have suggested
that maternal hyperoxygenation may inadvertently reduce
uterine blood flow, and that long-term oxygen therapy
may be associated with maternal pulmonary dysfunction
[121-123].
Amnioinfusion
Background
Amnioinfusion is a procedure whereby fluid (either saline
or Ringer's lactate) is added to the uterine cavity transcer-
vically via catheter, when the membranes have ruptured,
or transabdominally using a needle if amniotic mem-
branes are still intact. The procedure is often performed in
an effort to prevent or relieve umbilical cord compression
during labour associated with low amniotic fluid volume
(oligohydramnios); the infusion of fluid also dilutes
meconium detected in the amniotic fluid. Dilution of
meconium is thought to minimize the risk of meconium
aspiration, as thick meconium in cases of oligohydram-
nios is associated with significant perinatal mortality and
morbidity [124]. Amnioinfusion may impact fetal sur-
vival via one or both of these mechanisms and the two can
be difficult to differentiate. Amnioinfusion has also been
used in an effort to prevent ascending infection in cases of
premature rupture of membranes (PROM)[125], or to
facilitate external cephalic version at term, though the
impact of amnioinfusion for external cephalic version on
perinatal outcomes has not been examined [126]. The evi-
Table 8: Impact of maternal hyperoxygenation for impaired fetal growth on stillbirth and perinatal mortality
Source Location and Type of Study Intervention Stillbirths/Perinatal 
Outcomes
Reviews and meta-analyses
Say et al. 2003 [119] Italy, UK, South Africa.
Meta-analysis (Cochrane). 3 RCTs 
included (N = 94 women).
To assess the effects of maternal oxygen therapy 
(intervention) vs. management without additional 
oxygen (controls) in suspected impaired fetal 
growth on fetal growth and perinatal outcome.
PMR: RR = 0.50 (95% CI: 0.32 
– 0.81).
[15/46 vs. 31/48 in 
intervention and control 
groups, respectively].
Intervention studies
Battaglia et al. 1994 [120] Italy (Modena). Tertiary referral 
hospital (University of Modena).
Quasi-RCT. N = 38 patients with 
intrauterine growth retardation 
(N = 18 intervention group, N = 
20 controls).
Compared the impact on fetal survival of bed 
rest plus humidified 55% oxygen at a rate of 8 l/
min continuously (intervention) vs. bed rest (plus 
anti-hypertensive treatment, when necessary).
Ultrasound assessment of amniotic fluid volume 
was performed on alternate days, and the fetal 
abdominal circumference was evaluated weekly. 
Doppler analysis of fetal/maternal circulation was 
performed upon the patient's arrival at hospital, 
after 12 h, and thereafter on alternate days until 
parturition.
PMR: No deaths.BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2393/9/S1/S6
Page 30 of 43
(page number not for citation purposes)
dence for whether amnioinfusion for this variety of indi-
cations has any impact on perinatal mortality outcomes
has not been systematically compiled.
Literature-based evidence
The literature search identified 2 Cochrane reviews and 11
other interventional/observational studies, presented
below by indication (Table 9).
Amnioinfusion for PROM
The original Cochrane review by Hofmeyr et al. on amni-
oinfusion [125] evaluated 14 relatively small (<200 par-
ticipants) RCTs of amnioinfusion compared with no
amnioinfusion in pregnancies with PROM as a treatment
to alleviate umbilical cord compression and prevent intra-
uterine infection. There was no significant impact of
amnioinfusion compared with controls on perinatal mor-
tality (8 trials, RR = 0.51, 95% CI: 0.11–2.24) (Additional
file 25). Transcervical amnioinfusion for potential or sus-
pected umbilical cord compression reduced the risk of
fetal heart rate decelerations (4 trials, N = 227 women: RR
= 0.54; 95% CI: 0.43–0.68); Caesarean section (9 trials, N
= 953 women, RR = 0.52, 95% CI: 0.40–0.69), Apgar score
< 7 at 5 minutes (7 trials, N = 828 women, RR = 0.54, 95%
CI: 0.30–0.97), and low cord arterial pH (6 trials, N = 660
women, RR = 0.45, 95% CI 0.31–0.64). Transabdominal
amnioinfusion showed similar trends, though numbers
studied were too small to reach statistical significance.
Transcervical amnioinfusion to prevent infection in
women with membranes ruptured for more than six
hours (one trial of 66 women) was associated with a
reduction in puerperal infection (1 trial, N = 68 women,
RR = 0.50, CI 0.26–0.97) [LOE: 1-].
In a tertiary care facility in Italy, a quasi-RCT by De Santis
et al. 2003 [127] assessed the impact on fetal survival of
weekly transabdominal amnioinfusion in a group of
women with pre-term PROM at less than 26 weeks gesta-
tion (N = 71), reporting twice the survival rate among
fetuses born to women in the amnioinfusion group versus
the expectantly managed group (64.8% vs 32.3% of
fetuses survived, respectively, P < 0.01).
Amnioinfusion for oligohydramnios with intact membranes
A case-control study of women with oligohydramnios in
pregnancy (N = 100) by Chhabra et al. [128] administered
antepartum transabdominal amnioinfusion to 50
women, treating the remainder conservatively. The peri-
natal mortality rate was significantly lower among the
amnioinfusion group compared to controls given con-
servative management (4% vs. 18%, respectively) [LOE:
2++].
Prevention of meconium aspiration
A second Cochrane review by Hofmeyr [124] evaluated
RCTs (12 small trials) comparing amnioinfusion with no
amnioinfusion for women in labour under either normal
or limited perinatal surveillance with moderate or thick
meconium staining of the amniotic fluid (Additional file
26). Amnioinfusion was associated with significant reduc-
tions in heavy meconium staining of the amniotic fluid
(RR = 0.03, 95% CI: 0.01–0.15) and variable fetal heart
rate deceleration (RR = 0.65, 95% CI: 0.49–0.88). No peri-
natal deaths were reported. Under limited perinatal sur-
veillance, amnioinfusion was associated with a trend
towards reduced perinatal mortality (RR = 0.34, 95% CI:
0.11–1.06 [NS]), as well as significantly decreased risk of
meconium aspiration syndrome (RR = 0.24, 95% CI:
0.12–0.48), neonatal hypoxic ischaemic encephalopathy
(RR = 0.07, 95% CI: 0.01–0.56) and neonatal ventilation
or intensive care unit admission (RR = 0.56, 95% CI:
0.39–0.79); [LOE: 1+].
A large, multicentre RCT (56 centres, 13 countries, N =
1998 women) by Fraser et al. [129] of transcervical amni-
oinfusion versus standard care in women with thick
meconium staining reported 5 perinatal deaths in each
group, suggesting no beneficial impact of amnioinfusion
over standard care. The study also suggested the possibil-
ity that the risk of meconium aspiration syndrome could
be elevated rather than reduced after amnioinfusion rela-
tive to controls (RR = 1.39, 0.88–2.19 [NS]).
A matched case-control study by Ashfaq and Shah [130]
in Pakistan tested the impact of amnioinfusion in cases of
meconium stained liquor (N = 400 women). Both perina-
tal morbidity and mortality were reduced in the amnioin-
fusion group relative to controls (6% vs. 14%,
respectively), and the stillbirth rate was 0/200 (0%) in the
amnioinfusion group versus 8/200 (4%) in the control
group, though no statistical significance data was given.
The prevalence of meconium aspiration syndrome was
lower in the amnioinfusion group than among controls
(22% vs. 56%, respectively).
Several relatively small studies on amnioinfusion for
meconium staining in India reported lower rates of peri-
natal mortality in the amnioinfusion groups. A case-con-
trol study of amnioinfusion in women with meconium
staining (N = 250) reported substantially fewer deaths in
the amnioinfusion group than among controls (1/100
[1%] vs. 12/150 [8%], respectively, P = 0.01) [131]. Kiru-
bamani [132] tested the impact of intrapartum amnioin-
fusion with saline versus standard care in women with
light, moderate, or thick meconium (N = 50), and docu-
mented no deaths in the intervention group versus one
among controls (0/30 vs. 1/20, respectively). In West Ben-
gal, a study by Das et al. [133] of women in labour withBMC Pregnancy and Childbirth 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2393/9/S1/S6
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Table 9: Impact of amnioinfusion on stillbirth and perinatal outcomes
Source Location and Type of Study Intervention Stillbirths/Perinatal 
Outcomes
Reviews and meta-analyses
Hofmeyr 2002 [124] South Africa, Zimbabwe, USA.
Meta-analysis (Cochrane). 8 RCTs 
included (N = 1,481 women).
To assess the effects of amnioinfusion 
for meconium-stained liquor 
(intervention) vs. no amnioinfusion 
(controls) on perinatal outcome.
PMR: RR = 0.34 (95% CI: 0.11 – 
1.06) [NS].
[4/727 vs. 12/754 in intervention 
and control groups, respectively].
Hofmeyr 1998 [125] USA.
Meta-analysis (Cochrane). 8 RCTs 
included (N = 584 women).
To assess the effects of amnioinfusion 
(intervention) vs. no amnioinfusion 
(controls) on maternal and perinatal 
outcome for potential or suspected 
umbilical cord compression or 
potential amnionitis.
PMR: RR = 0.51 (95% CI: 0.11 – 
2.24) [NS].
[2/301 vs. 4/283 in intervention 
and control groups, respectively].
Intervention studies
Ashfaq 2004 [130] Pakistan (Karachi). Jinnah 
Postgraduate Medical Centre.
Matched case control study. N = 
400 patients between 1st January 
1998 to 31st December 2000 (N = 
200 intervention group, N = 200 
controls) with meconium staining of 
liquor.
Compared the impact on fetal 
outcome of amnioinfusion 
(intervention) vs. no amnioinfusion 
(controls) in cases of meconium 
staining.
SBR: 0/200 vs. 8/200 (4%) in 
intervention and control groups, 
respectively.
PMR/perinatal morbidity: 6% vs. 
14% in intervention and control 
groups, respectively (statistically 
significant).
Das et al. 2007 [133] India (West Bengal).
Prospective comparative study. 
Women (N = 150) who were in 
labour and had meconium-stained 
amniotic fluid (N = 50 intervention 
group, N = 100 controls).
Compared the impact of transcervical 
amnioinfusion (intervention) vs. 
standard care (controls).
PMR: RR = 0.31 (95% CI: 0.07 – 
1.31) [NS].
[2/50 (4%) vs. 13/100 (13%) in 
intervention and control groups, 
respectively].
Fraser et al. 2005 [129] 13 countries. Multicentered (56 
centers).
RCT. Pregnant women (N = 1998) 
in labour at 36 or more weeks of 
gestation who had thick meconium 
staining of the amniotic fluid. (81.3% 
of these women did not have 
recurrent variable decelerations in 
fetal heart rate on monitoring). N = 
995 intervention group, N = 1003 
controls).
Compared the impact of transcervical 
amnioinfusion (800 ml saline over 40 
min, followed by 2 ml/min to 1500 ml 
max; intervention) vs. standard care 
(no amnioinfusion) (controls). 
Women were assessed by continuous 
monitoring of intrauterine pressure 
or by uterine palpation at 15-minute 
intervals for signs of uterine 
overdistention or hypertonic 
contractions. Continuous electronic 
fetal heart-rate monitoring was 
performed in both groups.
PMR: RR = 1.00 (95% CI: 0.29 – 
3.45) [NS].
[N = 5 (0.5%) vs. N = 5 (0.5%) in 
intervention and control groups, 
respectively].
PMR, moderate or severe 
meconium aspiration syndrome, 
or both: RR = 1.26 (95% CI: 0.82 
– 1.95) [NS].
[44/986 (4.5%) vs. 35/989 (3.5%) 
in intervention and control 
groups, respectively].
Kirubamani 2000. [132] India.
RCT. N = 50 labouring women with 
clinically analysed meconium (light, 
moderate, thick) (N = 30 
intervention group, N = 20 
controls).
Compared the impact on perinatal 
mortality of amnioinfusion with warm 
saline at room temperature, along 
with standard obstetric care 
(intervention) vs. standard care only 
without amnioinfusion (controls).
PMR: 0/30 vs. 1/20 in intervention 
and control groups, respectively.
Mukhopadhyay et al. 2006 [153] India.
Quasi-RCT. N = 200 women (N = 
100 in each group).
Compared the impact on perinatal 
mortality of intraamniotic infusion of 
normal saline (intervention) vs. no 
amnioinfusion (controls).
PMR: 2/93 (2.1%) vs. 3/93 (3.2%) 
in intervention and control 
groups, respectively; P = 0.9748.BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2393/9/S1/S6
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meconium-stained amniotic fluid (N = 150) found that
the group that received transcervical amnioinfusion (N =
50) showed a possible trend toward reduced perinatal
mortality compared to a group (N = 100) receiving stand-
ard care (4% vs. 13%, respectively; RR = 0.31; 95% CI:
0.07–1.31). Rathore [134] performed a trial of amnioin-
fusion during labour for women with meconium staining
(N = 200), and found one stillbirth in the amnioinfusion
group and one stillbirth and one neonatal death in the
control group [LOE: 1+].
New meta-analysis
Our literature search identified ten randomised and quasi-
randomised trials reporting an impact of amnioinfusion
on stillbirths (9 trials, N = 1681 women) and perinatal
mortality (10 trials, N = 3656 women). Pooled analysis of
the impact of amnioinfusion on stillbirth incidence
revealed a non-significant reduction in risk associated
with amnioinfusion (RR [fixed] = 0.68, 95% CI: 0.19–
2.41 [NS]; RR [random] = 0.69, 95% CI: 0.19–2.43 [NS])
(Figures 8 and 9). Comparing the impact of amnioinfu-
sion versus controls without amnioinfusion on perinatal
deaths yielded a trend toward reduced mortality (RR =
0.51, 95% CI: 0.25–1.04, RR [random] = 0.52, 95% CI:
0.25–1.09 [NS]) (Figures 10 and 11).
Rathore et al. 2002 [134] India.
RCT. Women (N = 200) during 
labour with meconium stained 
amniotic fluid (N = 100 in each 
group).
Assessed the effect on perinatal 
deaths of amnioinfusion (intervention) 
vs. no amnioinfusion (controls).
PMR: 2 vs. 5 deaths in 
intervention and control groups, 
respectively.
SBR: 1 death in each group.
Early NMR (excluding 
malformations): 0 vs. 1 death in 
intervention and control groups, 
respectively.
Observational studies
Chhabra et al. 2007 [128] India.
Case-control study. Pregnant 
women (N = 100) with 
oligohydramnios (N = 50 study 
group, N = 50 controls).
Compared the impact of antepartum 
transabdominal amnioinfusion (cases) 
vs. conservative treatment without 
amnioinfusion (controls).
PMR: 4% vs. 18% in cases and 
controls, respectively (statistically 
significant).
Das 2001 [154] India.
Prospective case control study. 
Women (N = 290); (N = 100 
amnioinfusion group, N = 190 
controls).
Compared the impact on perinatal 
mortality of amnioinfusion 
(intervention) vs. no amnioinfusion 
(controls).
PMR: 1/100 vs. 16/190 in 
amnioinfusion and control 
groups, respectively; P = 0.01.
De Santis et al. 2003 [127] Italy. Tertiary care center.
Quasi-RCT. Women (N = 71) with 
pre-term premature rupture of 
membranes (pPROM) at <26 weeks 
of gestational age (N = 37 
amnioinfusion group, N = 34 
controls).
Compared the impact on fetal survival 
of serial transabdominal 
amnioinfusion with saline every 7 days 
in case of persistent oligohydramnios 
(intervention) vs. expectant 
management (controls).
Intrauterine fetal survival: 24/37 
(64.8%) vs. 11/34 (32.3%) in 
intervention and control groups, 
respectively, p < 0.01.
Halvax 2002 [155] Hungary. Tertiary referral hospital 
(University of Pecs).
Retrospective analysis. N = 228 
women (N = 118 amnioinfusion 
group, N = 110 controls).
Compared the impact of simultaneous 
use of fetal pulse oximetry and 
amnioinfusion in meconium stained 
amniotic fluid (intervention) vs. no 
amnioinfusion (controls). All 
monitored with cardiotocography.
Meconium below the vocal cords: 
0% vs. 10.1% in intervention and 
control groups, respectively; P < 
0.01.
Operative delivery rate: 22.0% vs. 
30.9% in intervention and control 
groups, respectively; P < 0.05.
Sahu 2003 [131] India.
Prospective case-control study. 
Women (N = 250) having 
meconium stained amniotic fluid 
during labour (N = 100 
amnioinfusion group, N = 150 
controls.
Compared the impact on perinatal 
mortality of amnioinfusion (study 
group) vs. no amnioinfusion 
(controls).
PMR: 1/100 (1%) vs. 12/150 (8%) 
in the study and control groups, 
respectively; P = 0.01.
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Conclusion
In low-resource settings, paediatric facilities for the man-
agement of meconium aspiration syndrome are scarce
and interventions to prevent meconium aspiration are
needed. Amnioinfusion, as one preventive option, is com-
paratively more feasible than management of meconium
aspiration syndrome in settings with limited intrapartum
facilities. Pooled data from the Hofmeyr meta-analysis
support the use of amnioinfusion for meconium stained
amniotic fluid to reduce the incidence of meconium aspi-
ration syndrome, with a trend toward reduced perinatal
mortality. However, the only large RCT on this subject by
Fraser et al [129], performed after the Cochrane review,
found no statistically significant impact on either meco-
nium aspiration syndrome or perinatal mortality, suggest-
ing the possibility of small study bias (an
overrepresentation of published small trials favouring a
treatment effect) in the Cochrane review [135].
For other antepartum and intrapartum indications for
amnioinfusion, including PROM, oligohydramnios with
intact membranes, alleviation of umbilical cord compres-
Meta-view: Impact of amnioinfusion for meconium-stained liquor on stillbirth (Random model) Figure 9
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sion, and prevention of infection after membrane rupture,
the available evidence is too limited to formulate recom-
mendations on the use of amnioinfusion. Some small
studies show promising differentials in mortality and
other outcomes between intervention and control groups,
but larger, more rigorous studies are needed to determine
the impact of amnioinfusion on these outcomes.
Further studies of amnioinfusion are needed to confirm
the obstetric indications and administration techniques
by which amnioinfusion might reduce perinatal mortal-
ity. When performing amnioinfusion in low-resource set-
tings, providers should remain vigilant about the risk of
infection if aseptic conditions are not maintained.
Meta-view: Impact of amnioinfusion for meconium-stained liquor on perinatal mortality (Random model) Figure 11
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Summary
While few studies reported consistent and statistically sig-
nificant evidence of impact on perinatal mortality associ-
ated with the intrapartum interventions we reviewed,
several interventions show promising indications of ben-
efit for specific indications or in certain settings. Induction
of labour rather than expectant management in post-term
pregnancies showed strong evidence of impact, though
the choice of drug(s) for induction of labour remains
unclear. Planned Caesarean section for term breech pres-
entation has been shown in a large RCT to reduce still-
births three-fold compared to vaginal breech delivery, but
questions of feasibility, potential enrolment bias, and
consequences of implementing this intervention rou-
tinely in low-/middle-income countries prevent a univer-
sal recommendation for its practice. Magnesium sulphate
for pre-eclampsia and eclampsia is effective in preventing
eclamptic seizures, but studies, many underpowered, did
not demonstrate an impact on perinatal mortality. Tran-
scervical amnioinfusion for meconium staining appears
promising for improving perinatal outcomes in low/mid-
dle income-country applications according to the findings
of many small studies, but a large randomised trial of the
intervention had no significant impact on perinatal mor-
tality Other novel interventions like maternal hyperoxy-
genation had statistically significant evidence of impact
on stillbirth, but the limited evidence base requires confir-
mation by other studies.
A distillation of the weight of the evidence for each of the
8 intrapartum interventions we reviewed is presented in
Table 10.
Implications for programmes
While the implementation of any of the interventions
examined in this paper could potentially prevent a still-
birth, multiple variables inherent to intrapartum care
influence the outcome and complicate comparison
between studies and assessment of the evidence of impact.
Drug dosages, route of administration, and regimens
often vary. The risk of a poor outcome of a forceps or vac-
uum extraction, or vaginal breech birth, is likely to be
lower in the hands of an experienced versus an inexperi-
enced practitioner. In the absence of adequate antisepsis
Table 10: Summary of evidence grading for all interventions during the intrapartum period to prevent stillbirth and perinatal 
mortality reviewed in this paper
Evidence of no or 
negative impact
(leave out of programmes)
Uncertain evidence
(need for additional 
research before including in 
programmes)
Some evidence
(may include in 
programmes, but further 
evaluation is warranted)
Clear evidence
(merits inclusion in 
programmes)
Instrumental delivery 
(vacuum vs. forceps)
X
(neither method superior, 
but either or both should be 
in programs)
Comprehensive emergency 
obstetric care packages, 
including Caesarean section
X
Induction of labour (vs. 
expectant management)
X
(for post-term pregnancy 
only)
Drugs for cervical ripening 
and induction of labour
X
Planned Caesarean for 
breech presentation
X
(attendant risks in low-
resource settings with poor 
EOC access)
Maternal hyperoxygenation 
for impaired fetal growth
X
(some evidence but 
biodynamics poorly 
understood)
Amnioinfusion X
Magnesium sulphate for pre-
eclampsia/eclampsia and 
pre-term labour
XBMC Pregnancy and Childbirth 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2393/9/S1/S6
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or availability of clean water supplies and antibiotics,
interventions such as instrumental delivery, Caesarean
section and amnioinfusion may increase the risk of harm
to the fetus or mother from infection, despite having been
developed to save these lives. Monitoring quality and con-
sistency during labour, prompt recognition of complica-
tions, and rapid performance of appropriate interventions
while avoiding inappropriate interventions that put
mother and fetus at unnecessarily increased risk are hall-
marks of obstetric care quality that are difficult to assess,
and likely varied, in the studies we reviewed.
The available evidence indicates broadly that where
women receive high-quality intrapartum care, including
monitoring of labour with access to operative delivery
(instrumental delivery, whether forceps or vacuum, or
Caesarean section), rates of perinatal deaths decrease. Par-
ticularly in low-resource settings, avoiding liberal use of
Caesarean section, even for breech presentation at term, is
advised.
Several interventions appear relatively well supported by
the evidence. Timely delivery in the presence of intrapar-
tum complications or maternal risk factors, often by Cae-
sarean section or instrumental delivery, can reduce
associated intrapartum stillbirth. This intervention is
largely credited for the relatively low rates of intrapartum
stillbirth in high-income countries [3]. Induction of
labour is beneficial at or after 41 or 42 weeks for post-term
pregnancy, especially if early ultrasound dating was per-
formed to confirm gestational age. Vacuum extraction and
forceps have different risks and benefits, but use of either
method is justified; more essential than the instrument
chosen is the need for facilities to be equipped to provide
safe instrumental delivery and Caesarean section.
Planned Caesarean section for breech delivery at term
reduces perinatal mortality three-fold compared to vagi-
nal breech delivery, and where most births are in facilities
that can provide safe Caesarean section, the available evi-
dence supports providers and their clients planning a Cae-
sarean section for breech presentation with informed
Table 11: Research gaps investigating interventions to prevent intrapartum stillbirths
Biodynamics and descriptive studies
• Frequency of uterine rupture in pregnancies subsequent to Caesarean section in rural settings
• Dynamics of maternal hyperoxygenation in placental perfusion and feto-placental circulation (risk or benefit to fetus?)
• Drug safety studies (fetal/neonatal outcomes): magnesium sulphate
• Safety of misoprostol for induction of labour
 Vaginal misoprostol optimal dosing and dose-range studies
Pilot/clinical/cohort studies of interventions
• Trials/comparisons of lesser-studied induction methods
 Extra-amniotic prostaglandins
 IV prostaglandins
• Feasibility and effectiveness of oral misoprostol administration in low-resource settings
• Foley catheter insertion for pre-induction cervical ripening
• Transabdominal amnioinfusion, especially in cases of intact membranes
• Effective interventions for pre-term labour
• Acceptability and utility of inexpensive manual vacuum extractors compared to forceps for assisted vaginal delivery
Rigorously designed large RCTs powered to detect impact on stillbirth
• Induction vs. expectant management for macrosomia and mild pre-eclampsia
• Comparison of first attempting assisted vaginal delivery in operating theatre vs. immediate Caesarean for obstructed labour in low-/
middle-income countries
• Distress-to-decision-to-incision studies for Caesarean in low-/middle-income country settings
• Planned Caesarean vs. vaginal breech trials to confirm or refute recommendation of Term Breech Trial for routine policy of planned 
Caesarean for breech
• Impact of hyperoxygenation on stillbirth rate
• Impact of amnioinfusion on stillbirth rate
Large effectiveness trials at scale or population level
• Unmet obstetric need studies reporting stillbirth outcomes (in addition to maternal impact)
• Association of facility quality improvement in comprehensive EOC/EmOC services with perinatal outcomesBMC Pregnancy and Childbirth 2009, 9(Suppl 1):S6 http://www.biomedcentral.com/1471-2393/9/S1/S6
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consent. In low-resource settings with poor access to
EmOC, however, having a Caesarean scar introduces risk
of subsequent poor pregnancy outcome and maternal
death, so vaginal breech delivery should be encouraged,
commensurate with skills of the birth attendants. Moreo-
ver, Goldenberg et al. [3] and McClure EM et al [21]
showed that population-based rates of Caesarean section
exceeding 10% had no further impact on stillbirth inci-
dence.
Research gaps
As research of intrapartum interventions reporting still-
birth as a primary or secondary outcome is rarely con-
ducted, many research gaps exist, making this an
important area for future research (Table 11). None of the
studies included in this review reported a consistent, sta-
tistically significant Grade A evidence of impact on still-
birth incidence. It follows that large RCTs (wherever
ethically and logistically possible) powered to detect
changes in stillbirth incidence are still needed for virtually
all the interventions we reviewed.
Conclusion
In settings where safe, comprehensive EOC is already
available, and diagnostic and monitoring capacity allow,
advanced interventions to manage pre-eclampsia,
PPROM, and oligohydramnios are needed. A few inter-
ventions examined in this review show strong evidence of
impact for certain indications, including Caesarean for
breech birth at term and induction of labour for post-term
pregnancy. There is some evidence that other interven-
tions such as amnioinfusion and maternal hyperoxygena-
tion may reduce perinatal mortality, but further research
on their safety and effectiveness in a range of settings is
required before they can be routinely included in pro-
grams. In areas without comprehensive essential obstetric
care capacity, it is key to prioritise improved access to
EmOC, especially vacuum extraction and Caesarean sec-
tion. EmOC is a package of clearly life-saving interven-
tions, and there is an association between countries with
high unmet obstetric need and intrapartum stillbirth rates
[3]. Safe EmOC, ideally as part of a package of compre-
hensive essential obstetric care services to address obstet-
ric problems before they become emergencies, will have
the greatest impact on intrapartum stillbirth rates in low-
resource settings, though expanding provision of EmOC
requires developing solutions for numerous logistical and
infrastructural challenges. These interventions would
need complementary measures to ensure staff training
and optimise delivery strategies in health systems.
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